1
Status: Approved ,Date: 18 April 2019Janssen Vaccines & Prevention B.V.
Clinical Protocol
A Randomized, Double -blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and 
Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV- Seropositive 
Toddlers 12 to 24 Months of Age
Protocol VAC18194RSV 2001; Phase 1/2a
Amendment 4
VAC1819 4 (Ad26.RSV.preF )
EudraCT NUMBER: 2017 -001345 -27 
Status : Approved
Date : 18 April 2019
Prepared by: [CONTACT_130328] & Prevention B.V.
EDMS number :EDMS- ERI-114933015, 14.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, per sons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is in dicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
2
Approved , Date: [ADDRESS_1072182] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 12
TIME AND EVENTS SCHE DULE –COHORT 0: A DULTS ....................................................................... 22
TIME AND EVENTS SCHE DULE –COHORT 1: SEROPOSITI VE TODDLERS ...................................... 24
ABBREVIA TIONS ...................................................................................................................................... 27
1. INTRODUCTION ................................................................................................................................ 29
1.1. Background .................................................................................................................................... 29
1.2. Overall Rationale for the Study ...................................................................................................... 34
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ........................................................................... 34
2.1. Objectives and Endpoints .............................................................................................................. 34
2.1.1. Objectives ................................................................................................................................... 34
2.1.2. Endpoints .................................................................................................................................... 35
2.2. Hypothesis ..................................................................................................................................... 37
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .37
3.1. Overview of Study Design .............................................................................................................. 37
3.2. RTI –Procedures Specific to Cohort 1 .......................................................................................... 45
3.3. Study Design Rationale .................................................................................................................. 46
3.4. Risk/Benefit Section ....................................................................................................................... 47
3.4.1. Known Benefits ........................................................................................................................... 47
3.4.2. Potential Benefits ........................................................................................................................ 47
3.4.3. Known Risks ............................................................................................................................... 47
3.4.4. Potential Risks ............................................................................................................................ 47
3.4.5. Overall Benefit/Risk Assessment ............................................................................................... [ADDRESS_1072183] POPUL ATION.................................................................................................................. 51
4.1. Inclusion Criteria ............................................................................................................................ 51
4.1.1. Adult Subjects ............................................................................................................................. 51
4.1.2. Pediatric Subjects ....................................................................................................................... 53
4.2. Exclusion Criteria ........................................................................................................................... 54
4.2.1. Adult Subjects ............................................................................................................................. 54
4.2.2. Pediatric Subjects ....................................................................................................................... 55
4.3. Prohibitions and Restrictions ......................................................................................................... 57
5. STUDY VA CCINE A LLOCA TION A ND BLINDING .......................................................................... 58
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 59
7. STUDY VA CCINE COMPLI ANCE.................................................................................................... 60
8. PRE-STUDY A ND CONCOMITA NT THERA PY............................................................................... 60
9. STUDY EVA LUATIONS .................................................................................................................... 61
9.1. Study Procedures ........................................................................................................................... 61
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
3
Approved , Date: 18 April [ZIP_CODE].1.1. Overview ..................................................................................................................................... 61
9.1.2. Visit Windows ............................................................................................................................. 62
9.1.3. Screening and Study Visits –Cohort 0 (Adults) ......................................................................... 62
[IP_ADDRESS]. Screening Phase: Days –28 to 1 ............................................................................................. 62
[IP_ADDRESS]. Active Phase –Day 1 to Day 211 ............................................................................................ 63
[IP_ADDRESS].1. Vaccination (Days 1 and 29) ................................................................................................ 63
[IP_ADDRESS].2. Post- first Vaccination Follow -Up.......................................................................................... 65
[IP_ADDRESS].3. Post- second Vaccinatio n Follow -Up.................................................................................... 65
[IP_ADDRESS].4. Final Visit –6 Months After the Second Vaccination ........................................................... 66
[IP_ADDRESS].5. Early W ithdrawal –Early  Exit Visit ....................................................................................... 66
[IP_ADDRESS]. Safety Follow -up Phase: Cohort 0 –After Day 211 ................................................................ 66
9.1.4. Screening and Study Visits –Cohort 1 (Seropositive Toddlers) ................................................ 66
[IP_ADDRESS]. Screening Phase: Days –42 to 1 ............................................................................................. 66
[IP_ADDRESS]. Active Phase –Day 1 to Day 211 ............................................................................................ 68
[IP_ADDRESS].1. Vaccination (Days 1 and 29) ................................................................................................ 68
[IP_ADDRESS].2. Post- first Vaccination Follow -Up.......................................................................................... 69
[IP_ADDRESS].3. Post- second Vaccinatio n Follow -Up.................................................................................... 69
[IP_ADDRESS].4. Early W ithdrawal –Early  Exit Visit ....................................................................................... 70
[IP_ADDRESS]. Safety Follow -up Phase: Cohort 1 –After Day 211 ................................................................ 70
9.2. Study Evaluations .......................................................................................................................... 71
9.2.1. Immunogenicity ........................................................................................................................... 71
9.2.2. Other Evaluations – RSV Infection ............................................................................................. 72
9.2.3. Safety Evaluations ...................................................................................................................... 73
[IP_ADDRESS]. Respi[INVESTIGATOR_60622] ..................................................................................................... 75
[IP_ADDRESS]. Clinical Laboratory Tests – Cohort 0 Only ............................................................................... 75
[IP_ADDRESS]. Vital Signs ................................................................................................................................ 77
[IP_ADDRESS]. Physical Examination .............................................................................................................. [ADDRESS_1072184] COMPLETION/D ISCONTINUA TION OF ST UDY VA CCINE/ WITHDRA WAL 
FROM THE STUDY ........................................................................................................................... [ADDRESS_1072185] etion ..................................................................................................................................... 77
10.2. Discontinuation of Study Vaccine/W ithdrawal from the Study ....................................................... 78
10.3. Contraindications to Vaccination .................................................................................................... 79
11. STATISTICA L METHODS ................................................................................................................. 80
11.1. Analysis Sets .................................................................................................................................. 80
11.2. Sample Size Determination ........................................................................................................... 80
11.3. Criteria for Explorator y Endpoints .................................................................................................. 81
11.3.1. Definitions for Exploratory Endpoints ......................................................................................... 81
[IP_ADDRESS]. Presence of Severe LRTI as Assessed by [CONTACT_15741] ............................................................... 81
[IP_ADDRESS]. Determination of RSV Positivity ............................................................................................... [ADDRESS_1072186] Information ........................................................................................................................ 82
11.5. Immunogenicity Analyses .............................................................................................................. 82
11.6. RSV Infection ................................................................................................................................ .82
11.7. Safety Analyses ............................................................................................................................. 82
11.8. Planned Analyses .......................................................................................................................... 83
11.9. Data Review Committees ............................................................................................................... 84
11.9.1. Independent Data Monitoring Committee (IDMC) ...................................................................... 84
11.9.2. Clinical Endpoint Committee (CEC) ........................................................................................... 84
11.10. Study Vaccination Pausing Rules .................................................................................................. 85
12. ADVERSE EVENT REPORT ING...................................................................................................... 86
12.1. Definitions ...................................................................................................................................... 87
12.1.1. Adverse Event Definitions and Classifications ........................................................................... 87
12.1.2. Attribution Definitions .................................................................................................................. 88
12.1.3. Severity Criteria .......................................................................................................................... 89
12.2. Special Reporting Situations .......................................................................................................... 90
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
4
Approved , Date: 18 April 201912.3. Procedures ..................................................................................................................................... 90
12.3.1. All Adverse Events ...................................................................................................................... 90
12.3.2. Serious Adverse Events ............................................................................................................. 91
12.3.3. Pregnancy (Cohort 0 Subjects) .................................................................................................. [ADDRESS_1072187] ................................................... 97
16.2.3. Informed Consent ....................................................................................................................... 98
16.2.4. Privacy of Personal Data ............................................................................................................ 99
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 99
16.2.6. Countr y Selection ....................................................................................................................... 99
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 100
17.1. Protocol Amendments .................................................................................................................. 100
17.2. Regulatory Documentation .......................................................................................................... 100
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_1072188] Identification, Enrollment, and Screening Logs .............................................................. 101
17.4. Source Documentation ................................................................................................................. 101
17.5. Case Report Form Completion .................................................................................................... 102
17.6. Data Qu ality Assurance/Quality Control ...................................................................................... [ADDRESS_1072189] Retention ......................................................................................................................... 103
17.8. Monitoring .................................................................................................................................... 103
17.9. Study Com pletion/Termination ..................................................................................................... 104
17.9.1. Study Com pletion/End of Study ................................................................................................ [ADDRESS_1072190] PA GE.............................................................................................................................................. 120
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
5
Approved , Date: [ADDRESS_1072191] OF A TTACHMENTS
Attachment 1: Toxicity Tables for Cohort 0 ...................................................................................... 110
Attachment 2: Toxicity Tables for Cohort [ADDRESS_1072192] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Study Design ............................................................................................................................. 16
Table 2: Summary  of Immunogenicity Assay s (Humoral) ...................................................................... 18
Table 3: Summary  of Immunogenicity Assay s (Cellular) ........................................................................ 19
Table 4: Other Ongoing Clinical Studies with Ad26.RSV.preF ............................................................... 32
Table 5: Study Design ............................................................................................................................. 40
Table 6: Summary  of Immunogenicity Assay s (Humoral) ...................................................................... 71
Table 7: Summary  of Immunogenicity Assay s (Cellular) ........................................................................ 72
FIGURES
Figure 1: Enrollment and First Dose Strategy .......................................................................................... 41
Figure 2: Schematic Overview of the Study for Cohort 0 ......................................................................... 43
Figure 3: Schematic Overview of the Study for Cohort 1 ......................................................................... 44
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
6
Approved , Date: [ADDRESS_1072193] 2017
Amendment 1 / Finland -1 29 September 2017
Amendment 1 / [LOCATION_006]-[ADDRESS_1072194] recent amendment.
Amendment 4 (Issued date: 18April 2019)
The overall reason for the amendment: This protocol amendment is made to reduce the overall number of RSV -
seropositive toddlers in the study from 48 to 36 .The rationale for this reduction is as follows:
As of 18April 2019, [ADDRESS_1072195] been enrolled in the current study (VAC1819 4RSV2001). The 
IDMC have reviewed available safety and immunogenicity data from the planned interim analysis , unblinded at 
the group level, when at least [ADDRESS_1072196]-Dose 2 data and 28 w ere in follow -up.
The IDMC concluded that the safety profile was acceptable and supported progression to the next study 
(VAC18194RSV2002) in RSV -seronegative toddlers aged 12 to 24 months in which subjects will receive half th e 
dose of Ad26.RSV.preF used in the current study (ie, 2.5x1010vp). In addition, blinded safety review by [CONTACT_780123]. Study  
VAC18194RSV2002 has already been initiated; as of 18April 2019, [ADDRESS_1072197] ation that there 
would be no difference in thelocal and systemic reactogenicity between seropositive and seronegative toddlers.
The c ollection of safety data at the planned dose in seronegative toddlers in study VAC18194RSV2002 w ill 
therefore add to the overall safety database in this age group as planned .Furthermore, as RSV -seropositive 
toddlers are at limited to no risk of severe RSV disease ,there would be limited value in continuation of the study .
The table below gives an overview of the rationale for each change and all affected sections
Rationale: As indicated above, the number of RSV -seropositive toddlers in this study is reduced from 48 to 36 .
Synopsis: Overview of Study Design ; Sample Size Determination 
3.1Overview of Study Design
11.2 Sample Size Determination
Amendment 3 (Issued date: 14November 2018)
The overall reason for the amendment: To potentially aid recruitment in the current study, t hisprotocol 
amendment is made to allow  enrollment of RSV seropositive toddlers who have been screened for a different 
clinical study of the sponsor (ie, VAC18194RSV2002) if RSV seropositivity was determined using the RSV EIA or 
virus neutralization assay.
Other updates and clarifications are made as specified below.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
7
Approved , Date: 18 April 2019The table below gives an overview of the rationale for each change and all affected sections
Rationale: Added clarification that RSV -seropositive subjects can be enrolled if their serostatus has been
confirmed by [CONTACT_780124] a different study of the sponsor .
Synopsis : Other Evaluations –RSV Infection
Time and Events Schedule
4.1.2 Inclusion Criteria –Pediatric Subjects
[IP_ADDRESS] Screening Phase: Days –42 to 1
9.2.2 Other Evaluations –RSV Infection
Rationale: Change of EIA cut-off criterion for seropositivity to titers >10 EIA units.
Synopsis: Other Evaluations –RSV Infection
9.2.2 Other Evaluations –RSV Infection
Rationale: Update of preclinical information .
1.1Background
Rationale: Update of clinical information.
1.1Background
Rationale: Clarification ofwording of Exclusion Criterion 23 for pediatric subjects .
4.2.2 Exclusion Criteria –Pediatric Subjects
Rationale: Clarification ofthe exclusion criterion for known allergies at screening refers to vaccines or vaccine 
components, but not to egg allergies .
4.2.2 Exclusion Criteria –Pediatric Subjects
Rationale: Clarification that the exclusion criterion for urticaria, eczema and atopic dermatitis relates to a 
moderate to severe history of these illnesses.
4.2.2 Exclusion Criteria –Pediatric Subjects
Rationale: Clarification that telephon e calls to subjects for RTI monitoring after the first dose w ill be made 
during both the active and safety follow -up phases .
Synopsis: Overview of Study Design
Time and Events Schedule
3.1Overview of Study Design
[IP_ADDRESS] Safety Follow -up Phase
Rationale: Clarification that during each [ADDRESS_1072198] -vaccination period , only RTIs for which a combination of 
respi[INVESTIGATOR_780090], w ill be reported .
Synopsis: RTI –Procedures Specific to Cohort 1 ; Other Evaluations –RSV Infection; Safety Evaluations
Time and Events Schedule
3.2RTI –Procedures Specific to Cohort 1
3.4.5 Overall Benefit/Risk Assessment
9.2.2 Other Evaluations –RSV Infection
Rationale: Clarification that in the event of an ongoing AE or other situation precluding subject vaccination 
within 10 days, subjects may be vaccinated beyond the 10 -day window  at the discretion of the sponsor.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
8
Approved , Date: 18 April 2019Time and Events Schedule
3.4.5 Overall Benefit/Risk Assessment
[IP_ADDRESS].1 Vaccination (Days 1 and 29)
[IP_ADDRESS].1 Vaccination (Days 1 and 29)
10.3 Contraindications to Vaccination
Rationa le: Clarification that any subject who receives study vaccine beyond the Day 29 w indow  specified in the 
Time and Events Schedule would not be included in the per -protocol immunogenicity analyses .
11.1 Analysis Sets
Rationale: For operational reasons, removal of the requirement for surveillance of primary care physicians, 
and/or hospi[INVESTIGATOR_600]’ urgent care facilities to monitor for subjects see king medical attention for an RTI .
3.4.5 Overall Benefit/Risk Assessment
Rationale: Specification that the [ADDRESS_1072199] 
within a ±14 days visit window.
Time and Events Schedule
9.1.2 Visit Windows
Rationale: Other minor changes, clarifications and corrections made throughout the protocol.
Amendment 2 (Issued date: 08January 2018)
The overall reason for the amendment:
This amendment is made to increase the number of seropositive toddlers by 12to generate additional safety data ,to 
specify post-vaccination monitoring time and to correct minor changes, clarifications and corrections made 
throughout the protoc ol.
The table below gives an overview of the rationale for each change and all affected sections
Rationale: To add 12extra seropositive toddlers to Cohort 1.
Synopsis
3.1Overview of Study Design
11.2 Sample Size Determination
Rationale: Removal of Attachment 3 containing information for sites in the [LOCATION_008] (remov al already 
effected via prior separate country -specific amendments : Clinical Trial Protocol Amendment 1 / Finland 1 –29 
September 2017 and Clinical Trial Protocol Amendment 1 / [LOCATION_006] 1 –03 October 2017 ).
3.4.2 Potential Benefits
Attachment 3
Rationale: Specification of monitoring time to be a minimum of [ADDRESS_1072200] -vacci nation in accordance 
with local approvals (change already effected via prior separate country specific amendment: Clinical Trial 
Protocol Amendment 1 / Finland 1 –29 September 2017) .
Synopsis
Time and Events Schedule
3.1Overview of Study Design
3.4.5 Overall Benefit/Risk Assessment
[IP_ADDRESS].1 Vaccination (Days 1 and 29)
[IP_ADDRESS].1 Vaccination (Days 1 and 29)
9.2.3 Safety Ev aluations
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
9
Approved , Date: 18 April 2019Rationale: Clarification that a least [ADDRESS_1072201] completed Visit 3 with no safety concerns before moving to vaccination of study subjects in a non -
clinic setting.
Synopsis
Time and Events Schedule
3.1Overview of Study Design
9.1.4 Screening and Study Visits –Cohort 1 (Seropositive Toddlers)
Rationale: Deletion of the wording “In addition, for a selection of tables, tabulations per dose by [CONTACT_780125].” , as the per dose analysis willno longer be carried out .
Synopsis
11.7 Safety Analysis
Rationale: Clarification that the unblinded pharmacist or other qualified individual will have no other study 
function from randomization onwards
Synopsis
3.1Overview of Study Design
5Study Vaccine Allocation and Blinding
6Dosage and Administration
14.3 Storage and Handling
Rationale: To specify thattheblood volume draw nfor serology testing will not exceed 15mL and adjust total 
blood volume that will be co llected .
Time and Events Schedule
9.1.1 Overview
Rationale: Other minor changes, clarifications and corrections made throughout the protocol.
Amendment 1 / [LOCATION_006] -1(Issued date: 03 October 2017)
The overall reason for the amendment:
This amendment is made to remove the offer of vaccination with a locally marketed vaccine w ith proven benefit for 
pediatric subjects for sites in the [LOCATION_008] as this provision was not endorsed by [CONTACT_780126].
The ta ble below gives an overview of the rationale for each change and all affected sections
Rationale: As above.
3.4.2 Potential Benefits
Attachment 3
Amendment 1 / Finland -1(Issued date: 29 September 2017)
The overall reason for the amendment:
This amendment is to clarify that, according to the requirements of the local ethics committee in Finland, the 
immediate post -vaccination observation period for toddlers in Cohort 1 should be a minimum of 60 minutes.
The table below gives an overview of the rationale for each change and all affected sections
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
10
Approved , Date: 18 April 2019Rationale: To clarify that the immediate post -vaccination observation period for toddlers in Cohort 1 should be a 
minimum of 60 minutes.
Synopsis
Time and Events Schedule
3.1 Overview of Study Design
3.4.5 Overall Risk/Benefit Assessment
[IP_ADDRESS].1 Vaccination (Days 1 and 29)
9.2.3 Safety Evaluations
Rationale: Removal of Attachment 3 containing information for sites in the [LOCATION_008].
3.4.2 Potential Benefits
Attachment 3
Amendment 1 (Issued date: 29August 2017)
The overall reason for the amendment:
This amendment is made to clarify that the responsibility to break the blind for emergency reasons rests solely with 
the investigator . Additionally, the following changes were made: the definition of probable RSV infection was 
removed; a reference to the Study Training Manual was deleted; the time periods for collections of concomitant and 
prestudy medications were clarified; stipulation that subjects should both measure and grade any in duration/ 
swelling in the subject diary was added; addition of virus neutralization assay as an alternative assay for assessment 
of RSV seropositivity at screening; and other minor inconsistencies were corrected .
The table below gives an overview of the rationale for each change and all affected sections
Rationale: To clarify that the responsibility to break the blind for emergency reasons rests solely with the 
investigator.
5Study Vaccination Allocation and Blinding
Rationale: The definition of probable RSV infection was dependent on the results of local laboratory testing, and as
only results from the central l aboratory w ould be considered as definitive ,the definition of probable RSV infection 
has been removed.
Synopsis
3.2RTI –Procedures Specific to Cohort 1
Rationale: Removal of reference to the Study Training Manual as this document is no longer produced.
9.1.1 Study Evaluations -Overview
Rationale: Clarification that collection of concomitant medications will be from the time of each vaccination until 
28 days after each vaccination, and that collection of pre- study therapi[INVESTIGATOR_780091] 30 days 
prior to vaccination.
Synopsis
Time and Events Schedule
3.1Overview of S tudy Design
8Pre-study and Concomitant Therapy
Rationale: Addition of virus neutralization assay as an alternative assay for assessment of RSV seropositivity at 
screening .
Synopsis
9.2.2 Other Evaluations –RSV Infection
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
11
Approved , Date: 18 April 2019Rationale: Clarification that the solicited local AE induration/swel ling should be both measured and graded by 
[CONTACT_780127] .
Synopsis
9.2.3 Safety Evaluations
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
12
Approved , Date: 18 April 2019SYNOPSIS
A Randomized, Double -blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and 
Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV -Seropositive Toddlers 
12 to 24 Months of Age
The adenovirus -vectored vaccine candidate assessed in this study is:
Ad26.RSV.preF (JNJ-64400141), a replication- incompetent adenovirus serotype 26 (Ad26) containing a 
deoxyribonucleic acid (DNA) transgene that encodes for the pre-fusion conformation- stabilized F protein 
(pre-F) derived from the respi[INVESTIGATOR_4345] (RSV) A2 strain .
OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
Objectives
Primary Objective s
 To assess the safety and tolerability of an intramuscular regimen of two doses of 1x1011viral 
particles ( vp)of Ad26.RSV.preF in adults aged 18 to 50 years .
 To assess the safety and tolerability of an intramuscular regimen of two doses of 5x1010vp of 
Ad26.RSV.preF in RSV -seropositive toddlers aged 12to 24 months .
Secondary Objective
 To assess the humoral and cellular immune responses as measured by [CONTACT_413384], 
F-protein binding antibodies (pre-F and post-F) and intrac ellular cytokine staining (ICS;to assess 
T-helper [ Th]1/Th2 subtypi[INVESTIGATOR_007] ).
Exploratory Objectives
 To further assess the humoral and cellular immune responses elicited by [CONTACT_300092]26.RSV.preF. The assays 
to be used may include, but are not limited to, RSV strain cross -neutralization, anti-Fprotein 
antibody specificity and functionality characterization, adenovirus neutralization assays, molecular 
antibody characterization (avidity, Fc cell interaction, antibody isotypi[INVESTIGATOR_007]), evaluation of the cellular 
immune response (interferon gamma [IFNγ ]enzyme -linked immunospot [ELISpot] assay) and 
functional and memory immune response (by [CONTACT_270052]), and cytokine profiles of RSV F-protein peptide -
stimulated peripheral blood mononuclear cell (PBMC) supernatant .
 To assess RSV infection rates in Ad26.RSV.preF and placebo subjects.
 To monitor for severe RSV -lower respi[INVESTIGATOR_1092] (LRTI) in Cohort 1 (RSV -seropositive 
toddlers aged 12 to 24 months) .
 To assess symptoms of respi[INVESTIGATOR_667106] (RTI) symptoms form.
Primary Endpoints – Safety and Tolerability
 Solicited local and systemic adverse events ( AEs)for 7 days after each vaccination.
 Unsolicited AEs for 28 days after each vaccination (ie, from informed consent form [ICF]signature 
[CONTACT_780191] [ADDRESS_1072202] vaccination, and for subsequent vaccinations from time of 
vaccination through the following 28 days ).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
13
Approved , Date: 18 April 2019 Serious adverse events ( SAEs )from ICF signature [CONTACT_780192].
Secondary Endpoints – Immune Responses
The analysis of the immunogenicity of vaccine regimens will include the characterization of humoral as 
well as cellular responses. The focus of the immunogenicity analysis is on virus neutralizing antibodies
(VNAs) , F-protein antibodies (pre- F and/or post -F) and Th1/Th2 cytokine profile response.
Humoral Immune Respons e
 RSV ne utralization A strain
Analysis of RSV A neutralizing antibodies .
 RSV F- protein enzyme -linked immunosorbent assay (ELISA; pre- and/or post -fusion F antibodies)
Analysis of antibodies binding to RSV F protein in post -fusion and pre -fusion form .
Cell-mediated Immune Response
 Intracellular cytokine staining or cytokine analysis*
Analysis of CD4 and CD8 T-cell subsets and their cytokine expression patterns will be determined 
by [CONTACT_780128] F-protein peptide stimulation (including, but not limited to CD4/CD8, 
interleukin -2 [IL -2], IFNγ, tumor necrosis factor alpha ( TNFα )and Th1/Th2 subtypi[INVESTIGATOR_007]).
*Cytokine analysis for Th1/Th2 profiling will be done in cases where no ICS data can be generated 
due to insufficient number ofPBMC sfor ICS assay (see exploratory endpoints below for 
description).
Exploratory Endpoints – Immune Responses
Additional exploratory analyses may be performed to investigate vaccine -elicited immune responses 
further. These m ay include, but are not limited to, the following assays :
Humoral Immune Res ponse
 RSV cross -neutralization of B and/or other A strain(s)
 F-protein antibody specificity characterization
 Adenovirus neutralization assay
 Functional and molecular antibody characterization
Cell-mediated Immune Response
 IFN ELISpot assay
 Cytokine analysis
Exploratory Endpoints – RSV Infection
 For Cohort 1only, RSV infection confirmed by [CONTACT_780129] (RT-PCR), or by [CONTACT_780130], but not limited to, protein G and/or N if no RT-PCR is 
available. To detect asymptomatic RSV infections, a fold increase will be applied to call a subject 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
14
Approved , Date: 18 April 2019seropositive to G and/or N ELISA (or F in case of placebo subjects). Fold increases for RSV 
infection will be determined based on the (suspected) infection and the co nvalescent blood samples. 
 In Cohort 1 throughout the study:
o Severe RSV -LRT I: for subjects in Cohort 1, severe RSV -LRTI will be defined as the presence 
of severe LRTI as assessed by [CONTACT_780131] (CEC) , and a positive assessment 
for RSV.
o RSV medically -attended respi[INVESTIGATOR_1092] (MA- RTI) : all subjects with RSV -RTI that is 
medically attended, ie,when the subject’s parent/legal guardian seeks medical attention outside 
of norm al study procedures, including health care professional’s visit to the home, clinic visit, 
emergency room attendance, and hospi[INVESTIGATOR_063]. (Note : medical attention outside normal 
study procedures will as much as possible also be captured on the RSV Symp toms Form .)
Note: Data on these 2exploratory endpoints will be collected to assess the feasibility of, and gain 
expertise in the collection of such events for future studies.
Hypothesis
No formal statistical hypothesis is planned. The study will evaluate whether Ad26.RSV.preF is safe, well -
tolerated and immunogenic in adults andRSV -seropositive toddlers .
OVERVIEW OF STUDY DESIGN
In this document, unless otherwise specified, any reference to activities to be performed by [CONTACT_780132] s or the parent/legal guardian for pediatric subjects.
This is a multi -center, randomized, double -blinda, Phase 1/2a study, to be conducted in 12male and 
female adults aged ≥18 to ≤50 years and 36male and female toddlers aged ≥12 to ≤24months of age, 
seropositive for RSV within 42 days prior to dosing .
Subjects will be enrolled into sequential age cohorts:
 18 to 50 year -old adults , into Cohort 0
 12 to 24 month- old seropositive toddlers, into Cohort 1
In Cohort 0, subjects will be randomized 2:1 to receive either Ad26/Ad26 (1x1011vpin 0.5 mL) or
placebo/placebo (saline) ,and in Cohort 1, subjects will be randomized 2:1 to receive either Ad26/Ad26 
(5x1010vpin 0.25 mL) or placebo/placebo ( Table 1).
The study will have three phases :a screening phase , an active phase and a safety follow-up phase
through [ADDRESS_1072203] dose. The durations of the respective phases are as follows:
                                                
aThe administrator of the vaccine may be unblinded but will not participate in any other study evaluation from 
randomization onwards. The site staff or qualified professional staff who will do the observation and the subjects 
will be blinded.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
15
Approved , Date: 18 April 2019Phase Cohort 0 Cohort 1
Screening: up to 4 weeks up to 6 weeks
Active: 30 weeks
dosing on Days 1 and 29
safety follow -up through [ADDRESS_1072204] -final 
dose
immunogenicity at:
 pre-Dose 1 (Day 1)
 pre-Dose 2 (Day 29)
 [ADDRESS_1072205] -Dose 2 (Day 57)
 [ADDRESS_1072206] -Dose 2
(Day 211/Week 30)30 weeks
dosing on Days 1 and 29
safety follow -up through [ADDRESS_1072207] -final 
dose
immunogenicity at:
 pre-Dose 1 (Day 1)
 pre-Dose 2 (Day 29)
 [ADDRESS_1072208] -Dose 2 (Day 57)
 [ADDRESS_1072209] -Dose 2
(Day 211/Week 30)
Safety follow -up: through [ADDRESS_1072210]’s last visit (by [CONTACT_756]) at the end of the safety 
follow -up phase.
An independent data monitoring committee (IDMC) will be established for this study to evaluate safety 
and tolerability data on a regular basis. An independent blinded CEC will be established for this study to 
assess any suspected case of severe LRTI in pediatric subjects.
First -dose Safety
For Cohort 0, 48-hour and 7-day safety will be monitored by [CONTACT_079] (s)(PI[s]) and the 
Study Responsible Physician (s)(SRP [s])a; for Cohort 1, 48- hour safety will be monitored by [CONTACT_978] (s)and 
the SRP(s), and 7-day safety will be monitored by [CONTACT_31849]. In the event of a significant safety finding, 
the IDMC will be consulted.
Note :At least [ADDRESS_1072211] 
completed Visit 3 with no safety concerns before moving to vaccination of study subjects in a non-clinic 
setting (safety information of the first 5 active toddlers will be monitored by [CONTACT_978](s)/SRP(s) through 
Visit 3, and escalated to the I DMC in the event of a safety signal).
Enrollment will be staggered to allow safety assessments to be made [ADDRESS_1072212] 12seropositive toddlers (8 actives and 
4placebos) in Cohort 1 before enrolling and dosing the remaining seropositive toddlers. These safety 
assessments are described more fully in Section 3.1. 
In addition, 48-hour safety will be checked after dosing sentinel subjects in both cohorts (2 subjects 
[1active and 1 placebo] in each cohor t).
Second- dose Safety
Post-second dose 48- hour and 7- day safety assessments will be monitored by [CONTACT_978] (s)and the SRP(s) .
Administration of the second dose will also be staggered to allow safety assessments to be made [ADDRESS_1072213] been establishe d in study 
VAC18193RSV1003 prior to initiation of the current study; the purpose of dosing Ad26.RSV.preF in Cohort [ADDRESS_1072214] formulation buffer, and consequently only PI 
[INVESTIGATOR_780092] 0 safety data is planned prior to dosing seropositive toddlers in Cohort 1. 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
16
Approved , Date: [ADDRESS_1072215] -vaccination safety on an ongoing basis by [CONTACT_780133] .
Table 1: Study Design
Cohort Group N Day 1 Day 29/Week 4 
ADULTS 18 to 50 years
0 Group 1 8 Ad26.RSV.preF (1x1011vp) Ad26.RSV.preF (1x1011vp)
Group 2 4 Placebo Placebo
TODDLERS 12 to 24 m onths: RSV seropositive
1 Group 3 24 Ad26.RSV.preF (5x1010vp) Ad26.RSV.preF (5x1010vp)
Group [ADDRESS_1072216] -vaccination according to local approvals , to monitor for the 
development of any acute reactions, or longer if deemed necessary by [CONTACT_093]. Any unsolicited, 
solicited local or systemic AEs and vital signs will be documented by [CONTACT_3449] -site personnel following this 
observation period. Subjectsawill be given a thermometer, ruler and daily assessment (subject) diary with 
instructions for the proper recording of events. Each subject will record solicited local (at injection site) 
and systemic AEs and body temperatures, beginning on the evening of each study vaccine dosing day and 
on a daily basis for the following [ADDRESS_1072217] diary information and confi rm the entries at 
subsequent site visits.
Unsolicited AEs will be collected from the time of informed consent through 28 days after each dose. For 
both cohorts, all SAEs will be collected from ICF signature [CONTACT_780192] . All AEs, including 
any that are ongoing at 28 days after each dose, will be followed until clinical resolution or stabilization. 
Concomitant medications will be collected from the time of each vaccination through 28 days after each 
vaccination, and additio nally outside of these periods when associated with any SAE.
Blood will be collected for immunogenicity assessments as follows:
Cohort 0: pre-vaccination for first and second doses, and at 28 days and 6 months after the second
dose
Cohort 1: pre-vaccination for first and second doses, and at 28 days and 6 months after the second 
dose
For Cohort 1, a blood sample will be taken for RSV serology at screeningd; the baseline sample for 
immunogenicity may either be drawn at the same screening visit or pre -dose on Day 1, at the discretion of 
the investigator.
                                                
aIn Cohort 1, activities to be performed by [CONTACT_780134]/legal guardian.
bRecommended orally for adult subjects; rectally or axillary for pediatric subjects (actual routes to be recorded in the eCRF).
cAll Day [ADDRESS_1072218]-vaccination diary assessments, including temperature measurements, may be collected earlier to coincide with 
the corresponding clinic visit.
d0.5 mL of blood for serostatus assessment can be collected by [CONTACT_780135], at the discretion of the 
investigator. If 0.5 mL is collected at screening, baseline blood draw for immunogenicity should be on Day 1.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
17
Approved , Date: 18 April 2019Safety Follow -up
Parents/legal guardians of subjects in Cohort 1 will be contact[CONTACT_5143] (or clinic visit) through [ADDRESS_1072219] dose (including during the active phase and safety follow -up pha se: every 30days ± 7 
days outside the RSV season, but every 14 days ± 3 days in season). During each 28- day post -vaccination 
period, c alls will remind parents/legal guardians to contact [CONTACT_780136]. During the RSV season, but outside the 28-day post-vaccination period, calls will remind 
parents/legal guardians to contact [CONTACT_780137] a combination of symptoms of 
respi[INVESTIGATOR_4416] ( persistent [>48 hours] clinical symptoms of rhinitis [sneezing or runny nose or 
congestion] and persistence [>24 hours] of one or more of the following: cough, abnormal breathing, 
fever, lethargy or decreased appetite ). These calls will also check for any SAEs and associated 
concomitant medications since th e previous visit or telephone contact.
RTI –PROCEDURES SPECIFIC TO COHORT [ADDRESS_1072220] dose (even if itfallsoutside of the 28-day post-vaccination period). 
Monitoring for MA -RTIs and severe LRTIs will take place during the whole study period.
During each 28-day post-vaccination period, all RTIs will be reported, nasal turbinate samples will be 
collected as soon as possible after the onset of respi[INVESTIGATOR_1856] , and signs and symptoms will be 
recorded by [CONTACT_780138]. 
If, during the RSV season, but outside the 28-day post-vaccination period, a subject shows persistent 
(>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and persistence 
(>24 hours) of one or more of the following30,32,41,44: cough, abnormal breathing, fever, lethargy or 
decreased appetite , the study site should be notified . Nasal turbinate samples will be collected as soon as 
possible after the onset of thesecombined respi[INVESTIGATOR_780093].When nasal turbinate samples are 
collected, the attending health care professional will record signs and symptoms of the R TI using the RTI 
Symptoms Form.
Nasal turbinate samples will not be collected if less than [ADDRESS_1072221] with a MA-RTI or 
severe LRTI.
The criteria used to assess potential cases of RSV infection in subjects from Cohort 1 will be as follows:
Suspected RSV infection : subject has persistent (>48 hours) clinical symptoms of rhinitis (sneezing 
or runny nose or congestion )and persistence (>24 hours) of one or more of the following: cough, 
abnormal breathing, fever, lethargy or decreased appetite . Occurrence of this combination of 
symptoms in any subject would trigger collection of a nasal turbinate sample.
Confirmed RSV infection: subject with suspected RSV infection and positive for RSV on the basis 
of RT -PCR conducted centrally .
                                                
aThese procedu res should preferentially be performed at the study site. These procedures can be conducted at the subject’s home 
by [CONTACT_780139]. In c ase of  
emergency, the procedures can be done in a hospi[INVESTIGATOR_307].
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
18
Approved , Date: [ADDRESS_1072222] POPULATION
Cohort 0: Healthy (on the basis of physical examination, medical history and vital signs measurement 
performed at screening) male or female adults , aged ≥18 to ≤50 years old on the day of ICF signature .
Cohort 1: Healthy (on the basis of physical examination, medical history and vital signs measurement 
performed at screening) male or female toddlers , aged ≥12 months to ≤24 months on the day ofICF 
signature [CONTACT_780193] 42days prior to dosing.
DOSAGE AND ADMINISTRATION
Ad26.RSV.preF (JNJ-64400141) will be supplied in single -use vials . Volumes of 0.5mL (1x1011vp) for 
adults and 0.25 mL (5x1010vp) for toddlers will be used for intramuscular injection into the deltoid of the 
non-dominant arm for adults and into either anterolateral aspect of the thigh for toddlers .
Placebo will be supplied as sterile 0.9% saline for injection .
An unblinded pharmacist , or other qualified indiv idual will prepare the appropriate vial and syringe and 
provide the syringe in a blinded manner to the study vaccine administrator who will perform the injection .
The unblinded pharmacist, or other qualified individual, may also perform the administration, but will have 
no other study function from randomization onwardsa.
For adult subjects, injections should be administered in the deltoid. For pediatric subjects, injections should 
be administered in the anterolateral aspect of the thigh. Alternating injection sites will be used for the 
vaccinations on Day [ADDRESS_1072223] operating procedures .
Table 2: Summary of Immunogenicity Assays (Hum oral)
Assay Purpose
Secondary endpoints
RSV neutralization A Analysis of neutralizing antibodies to the Astrain
F-protein antibody
(ELISA; pre- and/or post -fusion) Analysis of antibodies binding to RSV F protein in post -fusion and/or pre-
fusion form
Exploratory endpoints
RSV strain cross -neutralization Analysis of cross -neutralizing antibodies to B and/or a different A strain(s)
F-protein antibody specificity 
characterization Pre-and post -F specificity by [CONTACT_624661], 
and/or competition ELISA. Adsorption of serum or plasma with pre -F and 
post-F protein before any antibody assay, epi[INVESTIGATOR_111050], functional 
VNA
Adenovirus neutralization assay Analysis of neutralizing antibodies to adenovirus
Functional and molecular 
antibody characterizationAnalysis of antibody characteristics including ADCC, ADCP, avidity, Fc 
characteristics, Ig isotype, functi onal VNA and protective antibody 
assessments
ADCC = antibody -dependent cell-mediated cytotoxicity; ADCP = antibody -dependent cellular phagocytosis; ELISA = enzyme -
linked immunosorbent assay; F = fusion; Ig = immunoglobulin; RSV = respi[INVESTIGATOR_4345]; VNA = virus neutralizing 
antibod y
                                                
aThe unblinde d pharmacist, or other qualified individual, may also perform the administration, but will have no 
other study function from randomization onwards.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
19
Approved , Date: 18 April 2019Table 3: Summary of Immunogenicity Assays (Cellular)
Assay Purpose
Secondary endpoints
Flow  cytom etry (ICS)* Analysis of T -cell responses to RSV F -protein peptides for Th1/Th2 subtypi[INVESTIGATOR_780094]γ ELISpot T-cell IFNγ responses to RSV F -protein peptides
ICSAnalysis of T -cell responses to RSV F-protein peptide -stimulated PBMC s
(including but not limited to, CD4/CD8, IL2, INFγ, TNFα , activation markers and 
memory)
Cytokine analysisAnalysis of secreted cytokines in RSV F peptide -stimulated PBMC supernatant, 
including, but not limited to, measurement of Th1/Th2 cytokine balance
ELISpot = enzyme-linked immunospot; F = fusion; ICS = intracellular cytokine staining; IFNγ = interferon gamma; 
IL = interleukin; PBMC = peripheral blood mononuclear cell; Th= T-helper (cell); RSV = respi[INVESTIGATOR_4345]; 
TNFα = tumor necrosis fac tor alpha
* Cytokine analysis for Th1/Th2 profiling will be done in cases where no ICS data can be generated due to insufficient number of 
PBMCs for ICS assay
In addition to RT-PCR performed on a nasal turbinate sample collected at the time of infection, any 
immunogenicity blood sample collected from any Cohort [ADDRESS_1072224] who subsequently develops a 
suspected RTI may also be assayed by a serological assay (eg, ELISA specific to RSV protein G and/or 
N) to confirm RSV infection.
For adults, nasal turbinate samples , collected pre -dose on Days [ADDRESS_1072225]- Dose 1 (Day 8) and 
[ADDRESS_1072226]-Dose 2 (Day 57) will be used to assess any immunoglobulin (Ig) or cellul ar immune 
component.
OTHER EVALUATIONS –RSV INFECTION
RSV seropositivity of Cohort 1 subjects will be assessed by [CONTACT_780140] (EIA) or virus 
neutralizat ion assay at screening. The cut-off for seropositivity by [CONTACT_780141] a titer >10 EIA units and the 
cut-off by [CONTACT_780142] a titer >4.Note : RSV -seropositive toddlers may be recruited if 
RSV seropositivity wasassessed via either of these assays in a different study of the sponsor .
Nasal turbinate samples, taken from any Cohort [ADDRESS_1072227] with a specified combinationaof respi[INVESTIGATOR_780095] ( butoutside of the 28- day post -vaccination period), and from any Cohort [ADDRESS_1072228]’s 
parent/legal guardian will be asked to record the following AEs via the diary card :
Solicited local AEs for all subjects : erythema (measured using the ruler supplied), 
swelling/induration (measured using the ruler supplied and graded using the functional scale ), and 
pain/tenderness.
                                                
aPersistent (>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and persisten ce (>24 hours) of one 
or more of the following: cough, abnormal breathing, fever, lethargy or decreased appetite.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
20
Approved , Date: 18 April 2019Solicited systemic AEs for adult subjects : fatigue, headache, myalgia, arthralgia, chills, nausea and 
fever (ie, body temperature ≥38°C); for pediatric subjects : loss of appetite, vomiting, diarrhea, 
decreased activity/lethargy, irritability/crying and fever (ie, body temperature ≥38 °C).
Body temperatureashould be measured by [CONTACT_780143], 
preferably in the evening and, for pediatric subjects, additionally whenever the child feels warm using the 
thermometer supplied. All diary assessments, including body t emperature [ADDRESS_1072229]’s diary at the subsequent in-clinic visit; diary information will 
be transcribed by [CONTACT_780144] ( eCRF).
The investigator or study -site staff will document any reported unsolicited AEs and perform causality  
evaluations from the time of ICF signature [CONTACT_10782] [ADDRESS_1072230] signs and symptoms of the RTI using the RTI Symptoms Form. RTIs, preferably as a diagnosis, 
will also be reported on the AE page of the eCRF if they occur within 28 days following vaccination. Any 
RTI fulfilling the criteria of an SAE would be reported as such during the entire study. Any severe LRTI 
will be reported using the SAE reporting system and SAE form, regardless of whether the event fulfills 
the criteria of an SAE.
STATISTICAL METHODS
Sample Size Determination
The number of subjects chosen for this study will provide a preliminary safety and immunogenicity 
assessment. Placebo recipi[INVESTIGATOR_780096].
While mild to moderate vaccine reactions (local site and systemic responses) are expected, AEs that 
preclude further dose administration or more serious ones that would limit product development are not 
anticipated.
The following table shows the probabilities of o bserving at least one AE at given true AE rates:
True AE rate Probability of observing at least one AE in N subjects
N=4 N=8 N=12 N=24
0.5% 2% 4% 6% 11%
1% 4% 8% 11% 21%
2.5% 10% 18% 26% 46%
5% 19% 34% 46% 71%
10% 34% 57% 72% 92%
25% 68% 90% 97% 100%
50% 94% 100% 100% 100%
                                                
aRecommended orally for adult subjects; rectally or axillary for pediatric subjects (actual routes to be recorded in the eCRF) .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
21
Approved , Date: 18 April 2019Planned Analys es
The following analyses will be performed:
Cohort 0: primary analysis will be performed when all subjects have reached Day 57 ([ADDRESS_1072231]-Dose 2) or discontinued earlier. All available safety and immunogenicity data gathered so far 
will be included in the analysis; unblinded at the group level .
Cohort 1: interim analysis will be performed when at least [ADDRESS_1072232] reached Day 29 
(28days post -Dose 1) or discontinued earlier. All available safe ty and immunogenicity data gathered 
so far will be included in the analysis ; unblinded at the group level .
Cohort 1: primary analysis will be performed when all subjects have reached Day 57 ([ADDRESS_1072233]-Dose 2) or discontinued earlier. All available safety and immunogenicity data gathered so far 
will be included in the analysis; unblinded at the group level .
Final analysis of both cohorts ; at the end of the study, 1year after the first dose; unblinded
Additional interim analyses (blinded or unblinded at the group level) may be performed during the study 
for the purpose of informing future vaccine- related decisions in a tim ely manner, or upon health authority  
request. The results will not influence the conduct of the study in terms of early termination or later safety 
or immunogenicity endpoint assessments, and will only be available to a selected group of sponsor 
personnel, excluding sponsor personnel involved in data collection or data management .
Immunogenicity Analyse s
No formal hypothesis on immunogenicity will be tested. Descriptive statistics (geometric mean and 95% 
confidence interval (CI)for ELISA and virus neutralization assays; median and quartiles for ELISpot and 
ICS) will be calculated for continuous immunologi c parameters at all timepoints. Graphical 
representations of immunologic parameters will be made as applicable.
Frequency tabulations will be calculated for discrete (qualitative) immunologic parameters as applicable.
Safety Analyses
No formal statistical testing of safety data is planned. All safety data will be analyzed descriptively by 
[INVESTIGATOR_24858].
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
26
Approved , Date: 18 April 2019l.0.5 mL of blood for serostatus assessment can be collected at screening by [CONTACT_780135], at the discret ion of the investigator. If 0.5 mL is 
collected at screening, baseline blood draw  for immunogenic ity should be on Day 1 .
m.Note : RSV -seropositive toddlers may be recruited if RSV seropositivity was assessed via RSV EIA or virus neutralization assay in a different study of the sponsor .
n.Cohort 0: to include exclusion criteria 1, 4, 8, 9, 10, 11, 15, 16 and 17
o.Cohort 1: to include exclusion criteria 21, 22, 25, 26, 28, and [ADDRESS_1072234] check for acute illness or body temperature ≥38.0 °C at the time of vaccination. If beforethe first vaccination, the subject may be enrolled at a 
later date if within the screening window (otherwise, rescreening is required), or be withdraw n at the discretion of the investigator and after consultation with the 
sponsor .If before the second vaccination , the subject may be vaccinated up to, and no later than [ADDRESS_1072235] dose (even if it falls outside of 
the 28-day post-vaccination period). During each 28-day post-vaccination period, nasal turbinate samples will be collected for all RTIs. If, during the RSV season,
but outside the 28-day post-vaccination period, a subject shows persistent (>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and 
persistence (>24 hours) of one or more of the following: cough, abnormal breathing, fever, lethargy or decreased appetite, the study site should be informed and 
nasal turbinate samples will be collected for these subjects . Note : Nasal turbinate samples will not be collected if less than [ADDRESS_1072236] signs and symptoms of the RTI using the RTI Symptoms Form
v.At Visit 2, rulers and thermometers will be distributed to subjects in Cohort 0, and to parent(s)/legal guardian(s) of subjects in Cohort [ADDRESS_1072237] completed Visit 3 with no safety concerns before moving to 
vaccination of study subjects in a non-clinic setting (safety information of the first 5 active toddlers will be monitored by [CONTACT_978](s)/SRP(s) through Visit 3, and 
escalated to the IDMC in the event of a safety signal). 
x.Blood draw  for serology testing will not exceed 15mL
Note : Body temperatures for Cohort 0 recommended to be measured orally; body  temperatures for Cohort 1 recommended to be measured either rectal ly or axillary
(actual routes to be recorded in the eCRF)
AE = adverse event; d = day; eCRF = electronic case report form; EIA = enzyme immunoassay; FU = follow -up; HIV = human immunodeficiency virus; ICF = 
informed consent form; LRTI = low er respi[INVESTIGATOR_1092]; mo = month; MA-RTI = medically -attended respi[INVESTIGATOR_1092] ; RT-PCR = reverse transcriptase 
polymerase chain reaction; RSV = respi[INVESTIGATOR_4345]; RTI = respi[INVESTIGATOR_1092]; SAE = serious adverse event; vac = vaccination
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
27
Approved , Date: [ADDRESS_1072238] enhanced respi[INVESTIGATOR_780097] (set)
FDA (US) Food and Drug Administration
FI formalin -inactivated
FIH first-in-human
GCP Good Clinical Practice
β-hCG β-human chorionic gonadotropin 
HIV human immunodeficiency virus
ICF informed consent form
ICH International Conference on Harmonisation
ICS intracellular cytokine staining
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IFNγ interferon gamma
Ig immunoglobulin
IL interleukin
IRB Institutional Review Board
IWRS interactive web response system
LRTI lower respi[INVESTIGATOR_780098]-RTI medically -attended respi[INVESTIGATOR_780099] i nvestigator
PPI [CONTACT_340375]-protocol Immunogenicity (set)
PQC Product Quality Complaint
RSV respi[INVESTIGATOR_624611]-PCR reverse transcriptase polymerase chain reaction
SAE serious adverse event
SRP study responsible physician
S[LOCATION_003]R suspected unexpected serious adverse reaction
TB tuberculosis
Th T-helper (cell)
TNFα tumor necrosis factor alpha
[LOCATION_006] [LOCATION_008]
US [LOCATION_002]
VNA virus neutralizing antibody
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
28
Approved , Date: 18 April 2019vp viral particles
WHO World Health Organization
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
29
Approved , Date: 18 April [ZIP_CODE]. INTRODUCTION
A human adenovirus -vectored vaccine candidate which has shown promise in preclinical animal 
models of respi[INVESTIGATOR_227899] (RSV) will be assessed in this study :
Ad26.RSV.preF (JNJ-64400141), a replication -incompetent adenovirus serot ype 26 (Ad26) 
containing a deoxy ribonucleic acid (DNA) transgene that encodes for the pre-fusion 
conformation -stabilized F protein (pre -F) derived from the RSV A2 strain.
For the most comprehensive nonclinical and clinical information regarding Ad26.RSV.preF , 
refer to the latest version of the Investigator ’s Brochure for Ad26.RSV.preF .1
The term “sponsor ”used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Background
Background
RSV is considered to be the most important cause of serious acute respi[INVESTIGATOR_624615] [ADDRESS_1072239] 
infection (LRTI) in 2005, and 99% of these deaths occurred in developi[INVESTIGATOR_14696].[ADDRESS_1072240]  hyperreactivity  and 
asthma.36,38,40,42,43In the [LOCATION_002] (US), the infection rate was 68.8% in children younger 
than 12 months of age and 82.6% during the second year of life. Virtually all children had been 
infected at least once by [ADDRESS_1072241] vaccine 
candidate for young children, which consisted of formalin -inactivated RSV (FI-RSV), was 
associated with enhanced respi[INVESTIGATOR_23715] (ERD) upon infection with RSV.21Although the 
mechanisms for ERD are not fully  understood, it is thought that FI-RSV failed to induce 
adequate neutralizing antibody  titers and CD8 priming, and induced a T-helper (Th) 2skewed 
response.31
Adenoviral -vectored Vaccines
It is thought that an efficacious RSV vaccine should induce high levels of neutralizing 
antibodies, antigen -specific CD8+T-cell responses, and Th1-type CD4+T cells.3The candidate 
RSV vaccine being evaluated in this protocol is based on the AdVac®platform which has been 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
30
Approved , Date: 18 April 2019shown to promote a strong antibody  response, as well as CD8+T cell and Th1- type CD4+T-cell 
responses.
The immunogenicity  profile of adenoviral vectors, with particular emphasis on Th1 responses, is 
illustrated by [CONTACT_327961]26 -vectored human 
immunodeficiency  virus (HIV) vaccine (Ad26.ENVA.01), and of adults and infants with an 
adenovi rus serot ype 35 (Ad35 )-vectored tuberculosis (TB) vaccine (Ad35.TB -S). These data 
show predominantly  interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) 
production in CD4+and CD8+T cells.2,5,34Furthermore, in mice, Ad26 -and Ad35 -vectored 
vaccines with circumsporozoite (CS) transgene inserts (Ad26.CS.01 and Ad35.CS.01), when 
administered as single immunizations or in combination as a heterologous prime -boost regimen 
at dose levels ranging from 1x108viral particles (vp) to 1x1010vp, induce predominantl y CD8+
T-cell responses, as well as mainly  immunoglobulin (Ig) G2a antibody  respon ses, indicative of a 
Th1- biased response.[ADDRESS_1072242] upon infection with RSV, the likely Th1 profile of an adenoviral -vectored RSV 
vaccine reduces the likelihood of disease enhancement in RSV -seroneg ative infants.
Ad26.RSV.FA2 Clinical Data
Ad26 encoding for the wild-type RSV FA2, Ad26.RSV.FA2, has been evaluated in studies 
VAC18192RSV1001 and VAC18192RSV1003 (N = 48 and 32, respectively , of which 35 and 
24subjects, respectivel y, received Ad26.RSV.FA2) in adults at doses of 5x1010vp. All subject 
visits have been completed in both studies.
Results indicate that there have been no safet y concerns following vaccination in either study . 
After vaccination with Ad26.RSV.FA2, local reactogenicity  comprised almost exclusively  mild 
to moderate pain of median duration [ADDRESS_1072243] commonly  experienced solicited 
systemic adverse events (AEs; headache, fatigue, chills andmyalgia) were also most ly mild to 
moderate in severit y and of median duration 1 to 3 days; most unsolicited AEs and most 
laboratory  abnormalities were mild to moderate in severit y. No serious adverse events (SAEs) 
were reported and no AEs led to withdrawal from study  vaccine.
Single vaccination with 5x1010vp Ad26.RSV.FA2 raised humoral and cellular immunity . An 
increase in RSV neutralizing antibody  titers was observed; RSV -specific T- cell responses were 
also increased.
FA2 and preF RSV Vaccines
The candidate vaccine assessed in this study  is Ad26.RSV.preF, ie, a replication -incompetent 
Ad26 -containing a DNA transgene that encodes for the pre-fusion conformation- stabilized 
Fprotein derived from the RSV A2 strain.
First-in-human (FIH) clinical studies (VAC18192RSV1001 [FIH for Ad35.RSV.FA2] and 
VAC18192RSV1003 [FIH for Ad26.RSV.FA2]) have been completed with vaccines 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
31
Approved , Date: 18 April 2019Ad26.RSV.FA2 and Ad35.RSV.FA2 (ie, a similar recombinant, replication -incompetent vaccine 
using an Ad35 vector) , in which Ad26 and Ad35, respectivel y, encode for a wild-type RSV 
Fprotein of the RSV A2 strain.
The adenoviral vectors Ad26 and Ad35 are derived from Group B and D seroty pe adenoviruses 
and have been similarly modified to be replication incompetent ; expression of the antigen is 
controlled by [CONTACT_780145] r. An Ad26 -based RSV vaccine was chosen for further clinical 
development over the Ad35 -based counterpart based on a better immunogenicity  profile from 
nonclinical data, a similar safety  and immunogenicity  profile but at half the Ad35 dose from 
clinical dat a, and a better manufacturing profile.
The F protein of RSV F undergoes a conformational transition from a metastable pre-fusion 
conformation to a stable post -fusion conformation. Neutralizing sensitive epi[INVESTIGATOR_624616], but recent evidence indicates that those epi[INVESTIGATOR_624617] -F protein seem to be 
more potent than those previously  identified and present on the post -F protein.15,17This evidence
in the design of the candidate RSV vaccine (Ad26.RSV.preF) in which the adenoviral vector 
encodes for a full length RSV F protein stabilized in the pre-F protein conformation. The full 
length membrane -bound RSV F protein in a pre-F conformation encoded by [CONTACT_780146]-type F protein used in the FA2 construct.25This change 
in the transgene confers more stability  to the pre-fusion form of the protein .25This change also 
induces higher immune responses against pre-fusion epi[INVESTIGATOR_780100]-fusion protein conformation.27,33For these reasons, it is 
anticipated that the Ad26.RSV.preF vaccine candidat e will generate more neutralizing antibodies 
relative to the Ad26.RSV.FA2 vaccine .47
Ad26.RSV.preF Preclinical Data
In preclinical studies in mice and cotton rats, Ad26.RSV.preF is immunogenic, with humoral 
responses that include the induction of RSV neutralizing antibodies. In addition, in mice, it was 
shown that Ad26.RSV.preF elicits cellular responses, characterized by [CONTACT_624670] F-
specific CD8+ IFNγ+ T cells. The immune response following Ad26.RSV.preF immunization 
was T-helper 1 (Th1) -biased, based on the ratio of the Th1 cytokine IFNγ to Th2 cytokines, and 
on the ratio of RSV F-specific IgG2a/IgG1 antibod ies. Also, in neonatal mice, Ad26.RSV.preF 
was immunogenic and induced both humoral and cellular responses, with similar Th1 bias. In 
rodent models, single immunization with Ad26.RSV.preF induced dose-dependent protection in 
the upper and lower respi[INVESTIGATOR_780101] A2strain (in cotton rats 
and mice) and the RSV B strain (in cotton rats only). Histopathologic features of ERD were not 
observed in the lung after RSV challenge of mice and cotton rats vaccinated with 
Ad26.RSV.preF over a large dose range, including vaccine doses that were fully protective, as 
well as non- protective vaccine doses at which RSV replication in the lung was observed .47
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
32
Approved , Date: 18 April 2019Ad26.RSV.preF Clinical Data
Ad26.RSV.preF is currently  under evaluation in three other ongoing clinical studies: Phase 1 
study  (VAC18193RSV1003), and two Phase 2a studies (VAC18193RSV2002 and 
VAC18193RSV2003) (Table 4).
Table 4: Other Ongoing Clinical Studies with Ad26.RSV.preF
Study IdentifierClinical 
PhaseVaccine N Planned Study Population
VAC18193RSV1003 [ADDRESS_1072244] s aged 60 years and older
In one of these studies, interim safet y and immunogenicity data are available, as follows:
VAC18193RSV1003: This is an ongoing single -center, randomized, placebo -controlled, double -
blind, FIH, Phase [ADDRESS_1072245] received two intramuscular injections as follows:
Group 1 – 5x1010vp Ad26.RSV.preF on Day 1 and 1 year later;
Group 2 – 5x1010vp Ad26.RSV.preF on Day 1 and placebo 1 year later;
Group 3 – 1x1011vp Ad26.RSV.preF on Day 1 and 1 year later;
Group 4 – 1x1011vp Ad26.RSV.preF on Day 1 and placebo 1 year later;
Group 5 – placebo on Day  1 and 1 year later.
Safety  and immunogenicity  data from the unblinded (at the study  group level) analysis 28days 
post-dose [ADDRESS_1072246] s who received Ad26.RSV.preF (5×1010vp or 1×1011vp) or 
placebo confirmed that the 1×1011vp dose of Ad26.RSV.preF was more immunogenic compared 
with the 5×1010vp dose. Data from this ongoing study , which is still blinded, show that the 
Ad26.RSV.preF vaccine is immunogenic and that there is a favorable Th1/Th2 profile . No safety 
concerns were revealed; the reactogenicit y of both dos es was comparable .
For Study VAC18193RSV1003, Ad26.RSV.preF was provided in a different buffer 
(Formulation Buffer 1a) from the oneto be used in the current study  (Formulation Buffer 2b). 
The formulation buffer was changed to enhance the Ad26.RSV.preF dru g product stability  at 2 to 
8°C for storage purposes in future studies . The new formulation buffer was considered well-
                                                
CCI
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
33
Approved , Date: [ADDRESS_1072247] eted studies with Ad26.RSV.FA2 and one ongoing study  with 
Ad26.RSV.preF, the dose levels for Ad26.RSV.preF used in this study  are supported by 
[CONTACT_667134]26 vaccines encoding for different antigens (EnvA [in 
Ad26.ENVA.[ADDRESS_1072248] HIV];4,5CS protein [in Ad26.CS.[ADDRESS_1072249] malaria];10,34and Ebola 
glycoprotein [in Ad26.ZEBOV against Ebola virus ]29). Note that, in general, at a given dose 
level, no significant changes in the safet y profiles of Ad26 -based vaccines have been seen when 
the transgene has been changed.
In completed clinical studies,athe safet y of Ad26.ENVA.01, Ad26.CS.[ADDRESS_1072250] been complete d in adults: [ADDRESS_1072251] received Ad26.ZEBOV at 5x1010vp and 
1x1011vp without significant safet y issues: [ADDRESS_1072252] received 1x1011vp (25 doses 
administered), and [ADDRESS_1072253] only been tested in adults and the elderl y (ie,subjects 
≥18years); Ad35 -vectored vaccines have been tested in 904 subjects, including 555 adults and 
349 infants. Data from Bacillus Calmette -Guérin (BCG) -primed infants immunized with Ad35 
encoding for TB antigens (AERAS -402) indicated that the highest immune responses were 
obtained following administration of 1x1011vp. The safet y of this Ad35 -based TB vaccine was 
acceptable when tested in infants aged 14 weeks and older at doses from 1.5x108vp to 
1x1011vp.
Study Design
In the current study , homologo us regimens will be evaluated in subjects in two sequential 
cohorts .
In 18 to 50 y ear-old adults (Cohort 0): 
1x1011vp Ad26.RSV.preF (or placebo) on Day s 1 and 29
In 12 to 24 month -old RSV -seropositive toddlers (Cohort 1): 
5x1010vp Ad26.RSV.preF (or placebo) on Day s 1 and 29
                                                
aSafety data from these studies are summarized in a separate report (Adenoviral Vaccine Safety Database V2.0, December 2016) 
which is available on request.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
34
Approved , Date: 18 April 2019A dose of 1x1011vp will be used for adults in Cohort 0 based on an acceptable safet y profile of 
Ad26.RSV.preF at 1x1011vp from the unblinded (at the group level) interim analysis [ADDRESS_1072254]-Dose 1 from all 72 elderl y subje cts in study  VAC18193RSV1003, in addition to supporting 
safet y data from dosing Ad26.ZEBOV at 1x1011vp.
A dose of 5x1010vp will be used for toddlers in Cohort 1 as this is the anticipated dose to be 
used in a future study  in 12-24 month -old seronegative toddlers . Dosing ranging would occur in
a future stud y in 6 to 12 month- old seronegative subjects .
Enrollment and dosing will be staggered to allow safet y assessments to be made in adults before 
enrolling and dosing seropositive toddlers, as described fully  in Section 3.1below.
An independent data monitoring committee (IDMC )will be established for this study  to evaluate 
safet y and tolerability data on a regular basis. Refer to Section 11 .9.1, for details.
An independent blinded c linical endpoint committee (CEC) will be established for this study  to 
assess any suspected case of severe lower LRTI in pediatric subjects. Refer to Section 11.9.2, for 
details.
1.2. Overall Rationale for the Study
This study  seeks to evaluate the safet y and immunogenicit y of Ad26.RSV.preF at a dose of 
5x1010vpin RSV -seropositive toddlers aged 12 to 24 months (Cohort 1). As this is the first study 
using Ad26.RSV.preF in Formulation Buffer 2, the reactogenicity  profile of Ad26.RSV.preF in 
this new formulation buffer will be first assessed in an adult run-in coho rt (Cohort 0) before 
dosing the toddlers.
2. OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary Objectives
The primary objective s are:
To assess the safet y and tolerability  of an intramuscular regimen of two doses of 1x1011vp 
of Ad26.RSV.preF in adults aged 18 to 50 years.
To assess the safety  and tolerability  of an intramuscular regimen of two doses of 5x1010vp 
of Ad26.RSV.preF in RSV -seropositive toddlers aged 12 to 24 months.
Secondary Objective
The secondary  objective is:
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
35
Approved , Date: 18 April 2019To assess the humoral and cellular immune responses as measured by [CONTACT_780147] , F-protein binding antibodies (pre-F and post-F) and intracellular cytokine staining 
(ICS;to assess Th1/Th2 subty pi[INVESTIGATOR_007]).
Exploratory Objectives
The exploratory  objectives are:
To further assess the humoral and cellular immune responses elicited by [CONTACT_300092]26.RSV.preF. 
The assay s to be used may include, but are not limited to, RSV strain cross -neutralization, 
anti-Fprotein antibody specificit y and functionality  characteri zation, adenovirus 
neutralization assay s, molecular antibody  characterization (avidity , Fc cell interaction, 
antibody  isotypi[INVESTIGATOR_007]), evaluation of the cellular immune response (IFNγ enzyme-linked 
immunospot [ELISpot] assay ) and functional and memory  immune response (by [CONTACT_270052]), and 
cytokine profiles of RSV F-protein peptide- stimulated peripheral blood mononuclear cell 
(PBMC) supernatant .
To assess RSV infection rates in Ad26.RSV.preF and placebo subjects
To monitor for severe RSV -LRTI in Cohort 1(RSV -seropositive toddlers aged 12 to 
24months)
To assess symptoms of respi[INVESTIGATOR_667113] (RTI) symptoms 
form
2.1.2. Endpoints
Primary Endpoints –Safety and Tolerability
Solicited local and sy stemic AEs for 7 day s after each vaccination .
Unsolicited AEs for 28 days after each vaccination (ie, from informed consent form [ICF]
signature [CONTACT_780191] [ADDRESS_1072255] vaccination, and for subsequent 
vaccinations from time of vaccination through the following 28 day s).
SAEs from ICF signature [CONTACT_780194] y.
Secondary Endpoints –Immune Responses
The analysis of the immunogenicit y of vaccine regimens will include the characterization of 
humoral as well as cellular responses. The focus of the immunogenicity  analysis is on virus 
neutralizing antibodies (VNAs) , F-protein antibodies (pre-F and/or post-F) and Th1/Th2 
cytokine profile response.
Humoral Immune Response
RSV neutralization A strain
Analy sis of RSV A neutralizing antibodies.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
36
Approved , Date: 18 April 2019RSV F-protein enzy me-linked immunosorbent assay  (ELISA; pre-and/or post-fusion F 
antibodies)
Analy sis of antibodies binding to RSV F protein in post -fusion and pre -fusion form.
Cell-mediated Immune Response
Intracellular cy tokine staining or cy tokine anal ysis*
Analy sis of CD4 and CD8 T-cell subsets and their cytokine expression patterns will be 
determined by [CONTACT_780148]  F-protein peptide stimulation (including, but not 
limited to CD4/CD8, interleukin- 2 [IL- 2], IFNγ, TNF α andTh1/Th2 subty pi[INVESTIGATOR_007]).
*Cytokine analysis for Th1/Th2 pr ofiling will be done in cases wher e no ICS data can be 
generated due to insufficient number of PBMC sfor ICS assay (see exploratory endpoints 
below for description)
Exploratory Endpoints –Immune Responses
Additional exploratory  analyses may be performed to investigate vaccine -elicited immune 
responses further. These may include, but are not limited to, the following assay s:
Humoral Immune Response
RSV cross -neutralization of B and/or other A strain(s)
The strain cross -neutralizing capacit y of the vaccine -induced immune response will be 
assessed.
F-protein antibody  specificity  characterization
Pre-and post-F specificity  by [CONTACT_780149] s as ELISA, and/or competition 
ELISA. Adsorption of serum or plasma with pre-F and post-F protei n before any antibody  
assay , epi[INVESTIGATOR_111050], functional VNAs .
Adenovirus neutralization assay
This assay  assesses neutralizing antibody  responses against the adenoviral vector.
Functional and molecular antibody characterization
Functional characterization of antibodies may be performed in assay s including antibody -
dependent cell-mediated cy totoxicity  (ADCC) and antibody -dependent cellular phagocy tosis 
(ADCP).9A molecular characterization of vaccine -elicited antibodies will include antibody  
avidity , Fc characterization and Ig isotype, functional VNA and protective antibody  
assessments .
Cell-mediated Immune Response
IFNγELISpot assay
An ELISpot assay  is used to quantify  the amount of PBMCs able to produce IFNγ upon 
RSV F -protein peptide antigen stimulation.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
37
Approved , Date: 18 April 2019Cytokine anal ysis
Cytokine profiles of (in vitro) stimulated PBMC supernatant will be analy zed to assess the 
quantity  and qualit y of the elicited immune responses, including Th1/Th2 balance. Anal ysis 
will include, but is not limited to, I FN, IL-2, IL -4, IL -5, IL -13, and TNF .
Explor atory Endpoints –RSV Infection
For Cohort 1 onl y, RSV infection confirmed by [CONTACT_780150] (RT-PCR), or by [CONTACT_780151], but not limited to,protein G and/or N if no 
RT-PCR is available. To detect asymptomatic RSV infections, a fold increase will be 
applied to call a subject seropositive to G and/or N ELISA (or F in case of placebo subjects). 
Fold increases for RSV infection will be determined based on the (suspected) infection and 
the convalescent blood sample s.
In Cohort 1 throughout the study :
oSevere RSV -LRTI
oRSV medically -attended respi[INVESTIGATOR_2826] (MA -RTI)
Refer to Section 9.2for evaluations related to endpoints.
2.2. Hypothesis
No formal statistical hypothesis is planned. The study  will evaluate whether Ad26.RSV.preF is 
safe, well -
tolerated and immunogenic in adults a ndRSV -seropositive toddlers.
3. STUDY DESIGN A ND RA TIONA LE
In this document, unless otherwise specified, any reference to activities to be performed by [CONTACT_780152]/legal guardian for pediatric subjects.
3.1. Overview  of Stud y Design
This is a multi- center, randomized, double -blinda, Phase 1/2a study , to be conducted in 12 male 
and female adults aged ≥18 to ≤50 years and 36male and female toddlers aged ≥12 to 
≤24months of age , seropositive for RSV within 42 days prior to dosing .
Subjects will be enrolled into sequential age cohorts:
18 to 50 y ear-old adults, into Cohort 0
12 to 24 month- old seropositive toddlers , into Cohort 1
                                                
aThe administrator of the vaccin e may be unblinded but will not participate in any other study evaluation from 
randomization onwards. The site staff or qualified professional staff who will do the observation andthe subjects 
will be blinded.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
38
Approved , Date: 18 April 2019In Cohort 0, subjects will be randomized 2:1 to receive either Ad26/Ad26 (at 1x1011vp) or
placeb o/placebo ,and in Cohort 1, subjects will be randomized 2:1 to receive either Ad26/Ad26 
(at 5x1010vp) or placebo/placebo ( Table 5).
The standard dose (5x1010vp) is the dose the most commonly  used in previous studies and other 
programs with good safety  and immunogenicit y profiles. The high dose (1x1011vp) has been 
shown in study  VAC18192RSV1003 to be well tolerated in elderl y subjects and at least as 
immunogenic ,and is therefore appropriate foradults in this study . The standard dose is thought 
to be the proper dose to start with for preliminary ERD assessment in toddlers as ERD could be 
linked to a suboptimal immune response. The high dose will be first tested in further studies in 
seropositive toddlers ,before being usedin seronegative infants. Dose ranging will be performed 
in 6-12M seronegative, closer to the target population.
The study  will have three phases :a screening phase , an active phase and a safety follow -up 
phase through 1year after the first dose. The durations of the respective phases are as follows:
Phase Cohort 0 Cohort 1
Screening: up to 4 weeks up to 6 weeks
Active: 30 weeks
dosing on Days 1 and 29
safety follow -up through [ADDRESS_1072256] -final 
dose
immunogenicity at:
 pre-Dose 1 (Day 1)
 pre-Dose 2 (Day 29)
 [ADDRESS_1072257] -Dose 2 (Day 57)
 [ADDRESS_1072258] -Dose 2
(Day 211/Week 30)30 weeks
dosing on Days 1 and 29
safety follow -up through [ADDRESS_1072259] -final 
dose
immunogenicity at:
 pre-Dose 1 (Day 1)
 pre-Dose 2 (Day 29)
 [ADDRESS_1072260] -Dose 2 (Day 57)
 [ADDRESS_1072261] -Dose 2
(Day 211/Week 30)
Safety follow -up: through [ADDRESS_1072262]’s last visit (by  [CONTACT_756]) at the end of the 
safet y follow- up phase.
First -dose Safety
For Cohort 0, 48- hour and 7-day safety will be monitored by [CONTACT_079] (s)(PI[s]) 
and the Study  Responsible Physician(s) (SRP [s])a; for Cohort 1, 48 -hour safety  will be 
monitored by [CONTACT_978](s)and the SRP(s), and 7-day safet y will be monitored by [CONTACT_31849]. In the 
event of a significant safety  finding, the IDMC will be consulted.
Note : At least [ADDRESS_1072263] been established in study 
VAC18193RSV1003 prior to initiation of the current study; the purpose of dosing Ad26.RSV.preF in Cohort [ADDRESS_1072264] formulation buffer, and consequently only PI 
[INVESTIGATOR_780092] 0 safety data is planned prior to dosing seropositive toddlers in Cohort 1. 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
39
Approved , Date: [ADDRESS_1072265] completed Visit 3 with no safety concerns before moving to vaccination of study  subjects 
in a non-clinic setting (safet y information of the first 5 active toddlers will be monitored by [CONTACT_1600](s)/SRP(s) through Visit 3, and escalated to the IDMC in the event of a safet y signal).
Enrollment will be staggered to allow safety  assessments to be made [ADDRESS_1072266] 
12seropositive toddlers (8 actives and 4 placebos) in Cohort 1 before enrolling and dosing the 
remaining seropositive toddlers, as indicated below (see also Figure 1). In addition, 48-hour 
safet y will be checked after dosing sentinel subjects in both cohorts .The sentinel cohort 
approach with 2subjects (1active and 1placebo) in each cohort is taken to ensure active and 
placebo subjects are included in the evaluation s, taking into account the blinding. The 
observation at [ADDRESS_1072267] -dose is primarily  to rule out anaphy laxis or cytokine storm.
Enroll and dose 2 sentinel subjects (adults) in Cohort 0: 1of these 2sentinel subjects will 
receive Ad26.RSV.preF.
After satisfactory  completion of 48-hour safety review after the first dose for these 
[ADDRESS_1072268] dose. The PI(s)/SRP (s)will assess post-first dose reactogenicity  by [CONTACT_382239] 7-day 
safet y data for all 12 Cohort 0 subjects.
After satisfactory  completion of this safety  review, 2sentinel subjects (seropositive toddlers) 
in Cohort [ADDRESS_1072269] dose: one of these 2 sentinel subjects will 
receive Ad26.RSV.preF.
After satisfactory  completion of 48-hour safety review after the first dose for these 
[ADDRESS_1072270] 12 Cohort 1 subjects (8 actives and 4 placebos).
After satisfactory  completion of this safety  review, the remaining subjects in Cohort 1will 
be enrolled and receive the fir st dose .
In all post-first dose 48-hour and 7-day safety reviews, safety  data for review will include 
solicited and unsolicited AEs and SAEs. Additionally ,for Cohort [ADDRESS_1072271]-second dose 48-hour and 7-day safety assessments will be monitored by [CONTACT_978](s)and the 
SRP(s).Administration of the second dose will also be staggered to allow safet y assessments to 
be made [ADDRESS_1072272] 12 seropositive toddlers in Cohort 1 before administering the second 
dose to the remaining seropositive toddlers in Cohort 1. In addition, 48-hour safet y will be 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
40
Approved , Date: [ADDRESS_1072273]-vaccination safety  on an ongoing basis by [CONTACT_780153] y data.
Table 5: Study Design
Cohort Group N Day 1 Day 29/Week 4 
ADULTS 18 to 50 years
0 Group 1 8 Ad26.RSV.preF (1x1011vp) Ad26.RSV.preF (1x1011vp)
Group 2 4 Placebo Placebo
TODDLERS 12 to 24 m onths: RSV seropositive
1 Group 3 24 Ad26.RSV.preF (5x1010vp) Ad26.RSV.preF (5x1010vp)
Group 4 12 Placebo Placebo
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
42
Approved , Date: [ADDRESS_1072274]-vaccination according to local approvals, to 
monitor for the development of any acute reactions, or longer if deemed necessary  by [CONTACT_1275]. Any unsolicited, solicited local or systemic AEs and vital signs will be documented 
by [CONTACT_3449] -site personnel following this observation period. Subjectsawill be given a thermometer, 
ruler and daily  assessment (subject) diary  with instructions for the proper recording of events. 
Each subject will record solicited local (at injection site) and systemic AEs and body 
temperatures, beginning on the evening of each study  vaccine dosing day  and on a daily  basis for 
the following [ADDRESS_1072275] diary  information and confirm the entries at 
subsequent s ite visits.
Unsolicited AEs will be collected from the time of informed consent through 28 days after each 
dose. For both cohorts, all SAEs will be collected from ICF signature [CONTACT_780192] . All 
AEs, including any that are ongoing at 28 days after each dose, will be followed until clinical 
resolution or stabilization. Concomitant medications will be collected from the time of each 
vaccination through 28 days after each vaccination, and additionally  outside of these periods 
when associated with any  SAE.
Blood will be collected for immunogenicit yassessments as follows:
Cohort 0: pre-vaccination for first and second doses, and at 28 days and 6 months after the 
second dose
Cohort 1: pre-vaccination for first and second doses, and at 28 days and 6 months after the 
second dose
For Cohort 1, a blood sample will be taken for RSV serology  at screeningd; the baseline sample 
for immunogenicit y may either be drawn at the same screening visit or pre -dose on Day 1, at the 
discretion of the investigator.
Unscheduled study  visits may be performed based on inves tigator’s clinical judgment and may 
include further evaluations, as needed.
Diagram sof the entire study  design by [CONTACT_780154] 2(Cohort 0)andFigure 3
(Cohort 1) .
                                                
aIn Cohort 1, activities to be performed by [CONTACT_780134]/legal guardian.
bRecommended orally for adult subjects; rectally or axillary for pediatric subjects (actual routes to be recorded in the eCRF).
cAll Day [ADDRESS_1072276]-vaccination diary assessments, including temperature measurements, may be collected earlier to coincide with 
the corresponding clinic visit.
d0.5 mL of blood for serostatus assessment can be collected by [CONTACT_780135], at the discretion of the 
investigator. If 0.5 mL is collected at screening, baseline blood draw for immunogenicity should be on Day 1.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
45
Approved , Date: 18 April 2019appetite ). These calls will also check for an y SAEs and associated concomitant medications since 
the previous visit or telephone contact .
3.2. RTI – Procedures Specific to Cohort [ADDRESS_1072277] dose (even if itfallsoutside of the 28-day post-vaccination 
period). Monitoring for MA-RTIs and severe LRTI s will take place during the whole study  
period.
During each 28-day post-vaccination period, all RTIs will be reported , nasal turbinate samples 
will be collected as soon as possible after the onset of respi[INVESTIGATOR_23908], and signs and 
symptoms will be recorded by [CONTACT_780155] . 
If, during the RSV season, but outside the 28-day post-vaccination period, a subject shows 
persistent (>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and 
persistence (>24 hours) of one or more of the following30,32,41,44: cough, abnormal breathing, 
fever, lethargy  or decreased appetite , the study  site should be notified. Nasal turbinate samples 
will be collected as soon as possible after the onset of thesecombin edrespi[INVESTIGATOR_780102].
When nasal turbinate samples are collected, the attending health care professional will record 
signs and s ymptoms of the RTI  using the RTI S ymptoms Form .
Nasal turbinate samples will not be collected if less than 7 days after the previous sample 
collection.
Outside of the RSV season, nasal turbinate samples will only be collected from subjects with 
MA-RTIs or severe LRTI s(for definition of MA-RTI and severe LRTI, please refer to 
Section 11.3.1 ).
Throughout the study ,nasal turbinate samples will be collected from any subject with a MA -RTI 
or severe L RTI.
The criteria used to assess potential cases of RSV infection in subjects from Cohort 1 will be as 
follows:
Suspected RSV infection : subject has persistent (>48 hours) clinical symptoms of rhinitis 
(sneezing or runny nose or congestion) and persistence (>24 hours) of one or more of the 
following: cough, abnormal breathing, fever, lethargy  or decreased appetite .
Occurrence of this combination of symptoms in any subject would trigger collection of a 
nasal turbinate sample.
                                                
aThese procedure s should preferentially be performed at the study site. These procedures can be conducted at the subject’s home 
by [CONTACT_780139]. In c ase of  
emergency, the procedures can be done in a hospi[INVESTIGATOR_307].
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
46
Approved , Date: 18 April 2019Confirmed RSV infection : subject with suspected RSV infection and positive for RSV on 
the basis of RT -PCR conducted centrally .
Data on the clinical course of infection including information regarding oxygenation status, 
supplemental oxygen requirements and specific drug treatments should be collected, as well as 
any other concurrent respi[INVESTIGATOR_624637].
To ensure the rapid follow -up of any severe LRTI or MA-RTI, study  sites will need to make 
arrangements with primary  care phy sicians, emergency  departments and/or hospi[INVESTIGATOR_600]’ urgent care 
facilities to be notified when a subject is being seen. Further details will be provided in the Trial 
Center File.Any parent/legal guardian who seeks medical attention for their child due to an RTI 
should make the attending health care professional aware that their child is taking part in an RSV 
vaccine study . Each child’s parent/legal guardian will be given a wallet card with key study 
information and site contact [CONTACT_8972] (see Section 12.3.1 ). These details should be shared with the 
attending health care professional.
Note : Any RTI falling within the 28-day post-vaccination period will be reported as an 
unsolicited AE, preferably  as a diagnosis. Any RTI fulfilling the criteria of an SAE would be 
reported as such during the entire study .Any severe LRTI will be reported using the SAE 
reporting s ystem and SAE form, regardless of whether the event fulfills the criteria of an SAE.
3.3. Study Design Rationale
Dose Selection
The rationale behind selection of the Ad26 vector and dose selection is described in Section 1.1.
Availability of Safety Data Prior to Dosing
Two initial FIH studies (VAC18192RSV1001, N = 48;VAC18192RSV1003, N = 32) in health y 
adults examining homologous and heterologous regimens of 5x1010vp of Ad26.RSV.FA2 and 
5x1010vp of Ad35.RSV.FA2 have been completed. Both Ad26.RSV.FA2 and Ad35.RSV.FA2 
were sh own to be safe and immunogenic.
One subsequent FIH study  (VAC18193RSV1003, N = 72) in elderl y adults in stable health 
examining homologous regimens of 5x1010vp and 1x1011vp of Ad26.RSV.preF is ongoing. This 
study  uses Formulation Buffer 1. All [ADDRESS_1072278] dose. Based on acceptable safety  and immunogenicity  data from the unblinded (at the group 
level) interim analy sis [ADDRESS_1072279]-Dose 1 from all 72 subjects in this study , the current study 
will beinitiated firstl y for adults 18to 50 years of age. After 7 -day safety  has been verified by 
[CONTACT_978]/SRP in the first 12 adults, enrollment of seropositive toddlers 12-24 months of age will 
commence.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
47
Approved , Date: 18 April [ZIP_CODE].4. Risk/Benefit Section
3.4.1. Know n Benefits
The clinical benefits of vaccination with Ad26.RSV.preF have yet to be established.
3.4.2. Potential Benefits
Ad26.RSV.preF is under development for prophy laxis of RSV, however vaccine efficacy  has not 
yet been investigated. There is no direct medical benefit to the subject for participation in this 
clinical study . Although study  subjects may benefit from clinical testing and physical 
examination, they may receive no direct benefit from participation. Others may benefit from 
knowledge gained in this study  that may  aid in the developme nt of an RSV vaccine.
3.4.3. Know n Risks
Single doses of 5x1010vp or 1x1011vpof Ad26.RSV.preF are under investigation in the ongoing 
FIH Phase [ADDRESS_1072280]-Dose 1 from 41 subjects who received Ad26.RSV.preF 
or placebo did not reveal any  safet y concerns at either dose level.
3.4.4. Potential Risks
The following potential risks for Ad26.RSV.preF will be monitored during the study .
Risks Related to Vaccines
Subjects may exhibit local signs and symptoms associated with vaccination, including erythema, 
swelling/induration, and pain/tenderness. These local reactions will be monitored, but are 
generall y short -term and do not require treatment.
Subjects may  exhibit general signs and symptoms associated with administration of a vaccine, or 
vaccination with placebo, including fatigue, headache, myalgia, arthralgia, chills and nausea in 
adult subjects, and loss of appetite, vomiting, diarrhea, decreased activity /lethargy , 
irritability /crying in pediatric subjects. These side effects will be monitored, but are generally 
short -term and do not require treatment.
Subjects may have an allergic reaction to the vaccination. An allergic reaction may cause a rash, 
hives or even difficulty  breathing. Severe reactions, including anaphy laxis, are rare but can occur 
with any vaccine. Subjects with a known allergy , or history  of anaphy laxis or other serious 
adverse reactions to vaccines or vaccine components (including any of the constituents of the 
study  vaccine) will be excluded from the study . Sites should have medical treatment and 
medically  qualified staff available in case of severe allergic reactions following vaccine 
administration.
                                                
aAt the group level.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
48
Approved , Date: 18 April 2019Risks Related to Adenoviral -vectored Vaccines
Safety  data available from 10 completed clinical studies in adults with other Ad26 -vectored 
vaccine candidates, in which Ad26 with different inserts has been evaluated at dose levels 
ranging from 1x109vp to 1x1011vp, indicate that no safety  concerns would be anticipated from 
vaccination with Ad26.RSV.preF at doses of 5x1010vp and 1x1011vp.
Local AEs (moderate injection site pain and tenderness, and moderate to severe redness at the 
injection site) and systemic AEs (headache, chills, joint pain, muscle pain, tiredness/generall y 
not feeling well/fatigue and fever) have been reported after vaccination with Ad26 -vectored 
vaccines. In a few subjects, transient laboratory  abnormalities have been seen, including changes 
in neutrophils. Laboratory changes including decreased hemoglobin, decreased platelets, and 
moderate elevations in liver transaminases were observed that were not associated with any 
clinical findings and appear to be transient based on no reported persistent abnormalities in any 
of the subjects.
For further details on the safet y profiles of other Ad26 -vectored vaccine candidates, see the 
Ad26.RSV.preF Investigator’s Brochure.1
An Ad35 -vectored vaccine (AERAS -402) has been tested in two completed clinical studies in 
infants: data from these studies indicate acceptable safety  at doses from 1.5x108vp to 1x1011vp 
in infants aged 14 weeks and older.
Risks Related to RSV Vaccines
In the 1960s, a FI -RSV vaccine was associated with ER D in young children, characterized by  [CONTACT_780156] -mediated, severe LRTI in the vaccinated individuals compared with the 
control group.8,13,21,22Children aged between 2 months and 7 years of age were vaccinated; the 
risk of ERD was highest among children under [ADDRESS_1072281] 
severe outcomes, RSV infection was confirmed in 20/31 (65%) children who received the 
FI-RSV vaccine, with 16/20 children requiring hospi[INVESTIGATOR_780103] (52% of all 
FI-RSV vaccinees, representing 80% of those being RSV -infected). In contrast, while RSV 
infection was observed in 21/40 (53%) children who received a control vaccine, only one 
hospi[INVESTIGATOR_780103] (2.5% of all control vaccinees, representing 5% of those 
being RSV -infected) was required. Two of the FI-RSV vaccinated children died.22ERD is 
characterized by [CONTACT_780157].
Although the mechanisms for ERD are not fully understood, it is thought that FI-RSV: 1) may 
have failed to induce adequate neutralizing antibody  titers; 2) may  have led to an overproduction 
of binding antibodies promoting immune complex deposition and hypersensitivity  reactions; 
3)may have failed to induce adequate numbers of memory  CD8 T cells important for viral 
clear ance; and 4) may  have induced a Th2 -skewed allergic t ype T cell response.31
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
49
Approved , Date: [ADDRESS_1072282]. This Th1 profile of Ad26.RSV.preF reduces the likelihood of 
disease enhancement in RSV -seronegative infants.
Risks from Collection of Nasal Turbinate Samples
Collection of nasal turbinate samples may  cause a nosebleed.
Risks from Blood Draws
Blood drawing may cause pain/tenderness, bruising, bleeding, lightheaded ness, dizziness, 
vasovagal response, and, rarel y, infection at the site where the blood is taken.
Pregnancy and Birth Control (Cohort 0 Only)
The effect of the study  vaccine on a fetus or nursing baby [CONTACT_780158] [ADDRESS_1072283] vaccination (see Section 4.1). Use of 
hormonal contraception should start at least [ADDRESS_1072284]- feeding, or are planning to become pregnant while 
enrolled in the study  until 3months after the final dose of study  vaccine, will be excluded from 
the study . 
Subjects with Immuno -suppression/Reduced Immune Response
Limited evidence indicates that inactivated vaccines (or non-replicating viral vaccines) generall y 
have the same safety profile in immunocompromised patients as in immunocompetent 
individuals. However, the magnitude, breadth, and persistence of the immune response to 
vaccination may be reduced or absent in immunocompromised persons. Subjects with abnormal 
function of t he immune system will be excluded from the study .
Concomitant Vaccination 
Concomitant vaccination might have an influence on both safety  profile and immunogenicity  of 
Ad26.RSV.preF. Likewise, Ad26.RSV.preF might have an influence on both safet y profile and 
immunogenicit y of any concomitant vaccination. As a result, vaccination with live attenuated 
vaccines within 28 day s of a study  vaccination (ie, before and after) is prohibited. Other vaccines 
(eg, influenza, tetanus, hepatitis A, hepatitis B, rabies) sh ould be given at least 14 day s before (or 
at least 14 day s after) administration of study  vaccine. If a vaccine is indicated in a post-exposure 
setting (eg, rabies or tetanus), it must take priority  over the study  vaccine. Note : Planning for 
routine childh ood vaccinations will be available from the site to ensure that these can be taken at 
appropriate times during the study .
Unknown Risks
There may  be other serious risks that are not known.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
50
Approved , Date: 18 April [ZIP_CODE].4.5. Overall Benefit/Risk A ssessment
Based on the available data and pro posed safet y measures, the overall benefit/risk assessment for 
this clinical study  is considered acceptable for the following reasons:
Preliminary  safety data from the ongoing clinical studies and safety  data generated with the 
related vaccines containing different inserts revealed no significant safet y issues. 
Only  subjects who meet all inclusion criteria and none of the exclusion criteria (specified in 
Section 4) will be allowed to participate in this study . The selection criteria include adequate 
provisions to minimize the risk and protect the well -being of subjects in the study .
Safety  will be closel y monitored throughout the study:
After each vaccination, subjects will remain in the clinic and be closel y observed by [CONTACT_780159] [ADDRESS_1072285]-
vaccination according to local approvals, or longer if deemed necessary  by [CONTACT_1275], to monitor the development of any acute reactions. Any unsolicited, 
solicited local or sy stemic AEs will be documented during this period. Subjects will use a 
diary  to document solicited local and systemic AEs in the evening after each vaccination 
and then dail y for the next 7 days at approximately  the same time each day.
Subjects will undergo safety  follow -up by [CONTACT_464] 72 hours after each vaccination by 
[CONTACT_756]. 
Unsolicited AEs will be documented from immediatel y prior to until [ADDRESS_1072286]
vaccination.
Any clinicall y significant abnormalities (including those persisting at the end of the 
study /early  withdrawal) will be followed by [CONTACT_43727] a 
clinically  stable endpoint is reached.
Several safet y measures are included in this protocol to minimize the potential risk to subjects, 
including the following:
Enrollment will be staggered to allow safet y assessments to be made [ADDRESS_1072287] 12 seropositive toddlers 
(8actives and 4 placebos) before enrolling and dosing the remaining seropositive toddlers. 
For Cohort 0, 7 -day safety  will be monitored by  [CONTACT_978] [INVESTIGATOR_780104]; for Cohort 1, [ADDRESS_1072288] dose are described more full y in Section 3.1.
For all subjects, there are pre-specified rules that would result in pausing of further 
vaccinations if predefined conditions occur, preventing exposure of new subjects to study  
vaccine unti l the PI/SRP and/or IDMC reviews all safet y data (see Section 11.10 ).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
51
Approved , Date: 18 April 2019Subjects will discontinue study  vaccine for the reasons included in Section 10.2.
If acute illness (excluding minor illnesses such as diarrhea) or fever (body  temperature 
≥38.0°C) occur at the scheduled time for the first vaccination, the subject may be enrolled 
at a later datea, or be withdrawn at the discretion of the investigator and after consultation 
with the sponsor .
If acute illness (excluding minor illnesses such as diarrhea) or fever (body  temperature 
≥38.0°C) occur at the scheduled time for the second vaccination, the subject may be 
vaccinated up to [ADDRESS_1072289] vaccination within 10 
days, subjects may be vaccinated beyond the 10-day window at the discretion of the 
sponsor.
Contraindications to vaccination are included in Section 10.3.
Careful monitoring will be in place to check for incidence of any severe RSV -LRTI in 
Cohort [ADDRESS_1072290]-vaccination period, suspected cases of RSV 
infection will be identified for follow -upfrom a defined set of clinica l symptoms; nasal 
turbinate samples will be analy zed for identification and confirmation of RSV infection. 
Individual cases of severe L RTI may  be reviewed by  [CONTACT_31849].
4. SUBJECT POPULA TION
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following two subsections. If there is a question about the inclusion or exclusion criteria below, 
the investigator must consult with the appropriate sponsor representative and resolve any issues 
before enrolling a subject in the study .Waivers are not allowed .
Screening for eligible subjects will be performed within 28days before administration of the first 
dose of study  vaccine for Cohort 0, and within [ADDRESS_1072291] sign an ICF indicating that he or she understands the purpose of and 
procedures required for the study , is willing to participate in the study  and attend all 
scheduled visits, and is willing and able to comply  with all study  procedures and adhere to 
the prohibitions and restrictions specified in this protocol .
                                                
aIf within the screening window. Otherwise, rescreening is required.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
52
Approved , Date: [ADDRESS_1072292] is a man or woman, ≥18 to ≤ [ADDRESS_1072293] be healthy  on the basis of clinical laboratory  tests performed at screening. If 
the results of the laboratory  screening tests are outside the local laborat ory normal 
reference ranges and additionally  within the limits of toxicity  Grade 1 according to the US 
Food and Drug Administration (FDA) toxicity  tables (ie, for tests in the FDA  tablea), the 
subject may be included only if the investigator judges the abnormalities or deviations 
from normal to be not clinically  significant and appropriate and reasonable for the 
population under study . This determination must be recorded in the subject’ s source 
documents and initialed by  [CONTACT_093] .
Note : If laborator y screening tests are out of local laboratory normal ranges and deemed 
clinically significant, repeat of screening tests is permitted once using an unscheduled visit 
during the screening period to assess eligibility .
[ADDRESS_1072294] be either:
a.Not of childbearing potential defined as:
i.Premenarchal: a premenarchal state is one in which menarche has not yet 
occurred.
ii.postmenopausal: amenorrhea for at least 12 months without an alternative 
medical cause.
iii.permanentl y sterile: permanent sterilization methods include hysterectomy, 
bilateral salpi[INVESTIGATOR_1656], bilateral tubal occlusion/ligation procedures, and 
bilateral oophorectomy.
b.Of childbearing potential and
i.practicing an acceptable ef fective method of contraception. Acceptable methods 
for this study  include:
hormonal contraception;
intrauterine device;
intrauterine hormone -releasing s ystem;
male or female condom with or without spermicide;
cap, diaphragm or sponge with a vaginal spermicide;
vasectomized partner (the vasectomized partner should be the sole partner for 
that subject );
sexual abstinence*.
                                                
aFor the FDA toxicity grading tables, see Attachment 1: FDA Guidance document “Toxicity Grading Scale for Healthy Adult 
and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” (September 2007).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
53
Approved , Date: 18 April 2019*Sexual abstinence is considered an effective method only if defined as refraining 
from heterosexual intercourse from signing the informed consent until [ADDRESS_1072295] administration 
of study  vaccine.
Note : If the childbearing potential changes after start of the study (eg, a premenarchal 
woman experiences menarche) or the risk of pregnancy changes (eg, a wom an who is not 
heterosexually active becomes active,) a woman must begin an acceptable effective method 
of contraception, as described above.
[ADDRESS_1072296]:
a.Have a negative highl y sensitive serum β- human chorionic gonadotropin (β -hCG) 
pregnancy  test at screening
b.Have a negative urine β- hCG pregnancy  test immediatel y prior to each study vaccine 
administration
7From the time of first vaccination through [ADDRESS_1072297] agrees 
not to donate blood.
4.1.2. Pediatric Subjects
8 Each child’ s parent/legal guardian must sign an ICF indicating that he/she understands the 
purpose of and procedures required for the study , are willing for his/her child to participate 
in the study  and attend all scheduled visits, and are willing and able to comply  with all 
study  procedures, including maintaining contact [CONTACT_780160] 1yearfollowing the first 
dose, and adhere to the prohibitions and restrictions specified in this protocol .
Note : For each subject, at least one paren t, or legal guardian, according to local 
regulations, must give written consent .
9 Criterion amended per Amendment 3 :
9.[ADDRESS_1072298] is male or female, whose age on the day of ICF signature [CONTACT_832] ≥12* months to 
≤24months and who is seropositive for RSV.
Note : RSV-seropositive toddlers may be recruited if RSV seropositivity was assessed 
via RSV EIA or virus neutralization assay in a different study of the sponsor .In the 
event that a subject is not able to be randomized during the 42-day screening period, 
eg, due to illness or other circumstances, a subject may be rescreened and 
reconsented. However, a new serostatus blood sample would not be needed if the 
previous sample was deemed seropositive .
*Window of up to minus 2 weeks
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
54
Approved , Date: [ADDRESS_1072299] of a normal term pregnancy  ≥[ADDRESS_1072300] has received all routine immunizations appropriate for his or her age according to 
local guidelines.
13 Each child’ s parent(s)/legal guardian (s)must have access to a consistent means of contact 
[CONTACT_5640] b y telephone contact [CONTACT_52244]/computer.
4.2. Exclusion Criteria
4.2.1. Adult Subjects
1. Subject hasacute illness (this does not include minor illnesses such as diarrhea) or 
temperature ≥38.0 ºC/100.4 °F within [ADDRESS_1072301] (eg, compromise the well-
being) or that could prevent, limit, or confound the protocol-specified a ssessments.
3. Subject has history  of malignancy  within 5 years before screening (exceptions are 
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or 
malignancy , which is considered cured with minimal risk of recurrence) .
4. Subject has had major surgery  (per the investigator’s judgment), within [ADDRESS_1072302] dose 
of study  vaccine. Note : Subjects with planned surgical procedures to be conducted under 
local or locoregional anesthesia and not judged as major by [CONTACT_780161].
5. Subject has chronic active hepatitis B or hepatitis C infect ion, documented by [CONTACT_971] B 
surface antigen and hepatitis C antibody , respectively .
6. Subject has HIV t ype [ADDRESS_1072303] has had major psychiatric illness and/or drug or alcohol abuse which in the 
investigator’s opi[INVESTIGATOR_667114]’s safet y and/or compliance with the 
study  procedures.
8. Subject has current or past abuse of recreational or narcotic drugs or alcohol, which in the 
investigator’s opi[INVESTIGATOR_667114]’s safet y and/or compliance with the 
study  procedures.
9. Subject is in receipt of, or planning to receive, licensed live attenuated vaccine within 
28days of each study  vaccination (ie, before and after); other licensed vaccines (ie, not 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
55
Approved , Date: 18 April 2019live: eg, influenza, tetanus, hepatitis A, hepatitis B or rabie s) should be given at least 
14days before or [ADDRESS_1072304] dose of study  vaccine or is currently  enrolled or plans to 
participate in another investigational study  during the course of this study . Note : 
Participation in an observational clinical study (ie, with no interventi on) is allowed upon 
approval of the sponsor.
11. Subject has received treatment with Ig in the [ADDRESS_1072305] has a known allergy , or history  of anaphylaxis or other serious adverse reactions to 
vaccines or vaccine components (including an y of the constituents of the study  vaccine) .
13. Subject has a history  of chronic urticaria (recurrent hives), ecz ema and/or atopic dermatitis.
14. Subject has a history  of acute poly neuropathy  (eg, Guillain -Barré s yndrome).
15. Subject has abnormal function of the immune sy stem resulting from:
Clinical conditions (eg, autoimmune disease or immunodeficiency)
Chronic (longer than 10 days) or recurrent use of systemic corticosteroids during the 
study and within [ADDRESS_1072306] administration of study  vaccine (Note : ocular, 
topi[INVESTIGATOR_327865])
Administration of antineoplastic and immunomodulating agents or radiotherapy  during 
the study and within [ADDRESS_1072307] hasmoderate or severe illness (this does not include minor illnesses such as 
diarrhea) or temperature ≥38.0 ºC/100.4 °F within [ADDRESS_1072308] dose of study  
vaccine; enrollment at a later date is permitted.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
56
Approved , Date: [ADDRESS_1072309]’s weight is below 10th percenti le according to World Health Organization (WHO) 
pediatric growth and weight charts.7
23. Criterion amended per Amendment 3:
23.[ADDRESS_1072310] has any clinically  significant acute or chronic medical condition that, in the 
opi[INVESTIGATOR_871], would preclude participation :eg, history of seizure 
disorders, bleeding/clotting disorder, autoimmune disease, active malignancy , 
systemic infections, congenital heart disease, history  of any pulmonary condition 
requiring medication, atopy , reactive airway  disease, medicall y-confirmed wheezing, 
bronchoconstriction or treatment with a β2 agonist, cystic fibrosis, 
bronchopulmonary  dysplasia, chronic pulmonary  disease, medically -confirmed 
apnea, hospi[INVESTIGATOR_780105], or mechanical ventilation for respi[INVESTIGATOR_228851].
24. Subject has major congenital anomalies or known cytogenetic disorders (eg, Down’s 
syndrome).
25. Subject has had major surgery  within the [ADDRESS_1072311] is in receipt of, or planning to receive, live attenuated vaccine (eg, measles, mumps 
and rubella [MMR] or varicella, but excluding rotavirus vaccine) within 28 days of each 
study vaccination (ie, before and after); other vaccines (eg, influenza, pertussis, polio or 
rotavirus) should be given at least 14 days before or 14 days after each study  vaccination. 
Note : Planning for routine childhood vaccinations will be available from thesite to ensure 
that these can be taken at appropriate times during the study .
27. Subject has known or suspected immunodeficiency , such as known HIV infection.
28. Subject has received an investigational drug or used an invasive investigational medical 
device within [ADDRESS_1072312] dose of study  vaccine or is currently  enrolled or plans to 
participate in another investigational study  during the course of this study . Note :
Participation in an observational clinical study (ie, with no intervention) is allowed upon 
approval of the sponsor.
29. Criterion amended per Amendment 3:
29.[ADDRESS_1072313] has a known allergy to vaccines or vaccine components (including any  of the 
constituents of the study  vaccine) , or history  of anaphy laxis or other serious adverse 
reactions to vaccines or vaccine components (including any of the constituents of the 
study  vaccine). Note : subj ects with egg allergies can be enrolled.
30. Criterion amended per Amendment 3:
30.[ADDRESS_1072314] has a history  of the following moderate to severe chronic conditions: 
urticaria (recurrent hives), eczema and/or atopic dermatitis.
31. Subject has a history  of acute poly neuropathy  (eg, Guillain -Barré s yndrome).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
57
Approved , Date: [ADDRESS_1072315] has chronic or recurrent use of immunomodulators/suppressors, eg, cancer 
chemotherapeutic agents, oral or parenteral corticosteroids for at least [ADDRESS_1072316] has been in receipt of palivizumab/Sy nagis®or received any other vaccine or 
monoclonal/poly clonal antibody  in a previous RSV study at any time prior to 
randomization.
34. Subject has a contraindication to intramuscular injections and blood draws, eg, bleeding 
disorders.
35. Subject has a history  of an underl ying clinically  significant acute or chronic medical 
condition or physical examina tion findings for which, in the opi[INVESTIGATOR_871], 
participation would not be in the best interest of the subject (eg, compromise the well-
being) or that could prevent, limit, or confound the protocol- specified assessments.
36. Subject’s parent (s)/legal guardian(s) cannot communicate reliabl y with the investigator.
37. Subject is a family  member of either the investigator, study -site employ ee, or employ ee of 
the sponsor.
Note:Investigators should ensure that all study  enrollment criteria have been met at screening. If 
a subject’s clinical status changes (including any available laboratory results or receipt of 
additional medical records) after screening but before the first dose of study  vaccine is given 
such that he or she no longer meets all eligibility  criteria, then the subject should be excluded 
from participation in the study . Section 17.4, Source Documentation, describes the required 
documentation to support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restricti ons during the course of the stud y to be eligible for participation:
1.Refer to Section 8, for details regarding prohibited and restricted therapy  during the stud y.
2.Agree to follow all requirements that must be met during the study  as noted in the inclusion 
and exclusion criteria (Section 4.1.1 and Section 4.2.1 , respectivel y, for adult subjects, and 
Section 4.1.2 and Section 4.2.2 , respectivel y, for pediatric subjects).
3.Vaccination with live attenuated vaccines within 28 days ofa study  vaccination (ie, before 
and after) is prohibited. Other vaccines (eg, influenza, tetanus, hepatitis A, hepatitis B, 
rabies) should be given at least 14 days before (or at least 14 days after) administration of 
study  vaccine in order to avoid potential confusion of adverse reactions and potential 
immune interference. If a  v accine is indicated in a post-exposure setting (eg, rabies or 
tetanus), it must take priority  over the study  vaccine.
4.Cohort 1 only: Subjects should receive all routine immunizations according to applicable 
national guidelines. A subject will not postpone, forego or delay  the receipt of any 
recommended vaccine according to local schedules (eg, in Europe , the applicable national 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
58
Approved , Date: 18 April 2019immunization schedules ,11and the equivalent in other countries) due to participation in the 
current stud y. All subjects should receive routine immunizations according to schedule.
5. STUDY V ACCINE ALLOCA TION AND BLIND ING
Study Vaccine Allocation
Central randomization will be implemented in this study . Within each cohort, subjects will be 
randomly  assigned to one of the two groups based on a computer -generated randomization 
schedule prepared before the study  by [CONTACT_43754]. The 
randomization will be balanced by [CONTACT_576670]. Initially  2 sentinel subjects 
(one Ad26.RSV.preF and one placebo) will be enrolled to monitor for any unexpected severe 
adverse reaction to the vaccine. Therefore, the randomization of the first block will be phased to 
accommodate this. The remainder of the blocks will be filled to have an overall 2:1 
randomization ratio. No stratification will be applied. The interactive web response system 
(IWRS) will assign a unique code, which will dictate the group assignment for the subject. The 
requestor must use his or her own user identification and personal identification number when 
contact[CONTACT_23790], and will then give the relevant subject details to uniquely  identify  the 
subject.
If randomized subjects are withdrawn from vaccination before the first dose is administered, 
additional subjects may be recruited to replace these subjects at the discretion of the sponsor. 
Any replacement subject will be assigned to the same group as the original (discontinued) 
subject . The replacement subject’s randomization number will equal the randomization number 
of the discontinued subject [PHONE_3548] (for example subject [ADDRESS_1072317] 
1001). These additional subjects should also be randomized through I WRS .
Any randomized subject who is withdrawn from the study  for reasons other than due to an AE 
after the first dose but before the second dose might be replaced at the discretion of the sponsor. 
Any replacement subject will be assigned to the same group as theoriginal (discontinued) 
subject. The replacement subject’s randomization number will equal the randomization number 
of the discontinued subject [PHONE_16276].
Blinding
The investigator will not be provided with randomization codes until the final analysis is 
performed . The codes will be maintained within the IWRS, which has the functionality  to allow 
the investigator to break the blind for an individual subject.
Unblinding (ie, at the subject level) will only occur at the time of database lock of the final 
analysis. While the responsibility  to break the study  vaccine allocation code in emergency  
situations resides solely  with the investigator, it is recommended that the investigator contact [CONTACT_780162], before breaking the blind. Telephone 
contact [CONTACT_97500] 24hours per day, 7days per week. In 
such cases, the investigator may in an emergency  determine the identity  of the study  vaccine by 
[CONTACT_23793]. In the event the blind is broken, the sponsor must be informed as soon as 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
59
Approved , Date: [ADDRESS_1072318] be documented by[CONTACT_8784], in the 
appropriate section of the electronic case report form (eCRF ), and in the source document .The 
document ation received from the IWRS indicating the code break must be retained with the 
subject’s source documents in a secure manner.
The subjects, study -site personnel, and investigator, and sponsor personnel will be blinded to 
study  vaccine allocation throughout the study , except for the pharmacist or qualified staff 
member with primary  responsibility  for study  vaccine preparation and dispensing. The pharmacy  
and preparation of study vaccines will be monitored by [CONTACT_576672] 
(see Section 17.8).
Note : the unblinded pharmacist, or other qualified individual, may also perform the vaccine 
administration, but will have no other study  function from randomization onwards.
The primary  analysis, and any other interim analysis performed before the final analy sis, will be 
performed on data unblinded at the group levela; there will be no unblinding at the subject level. 
These data will only be available to a selected group of sponsor personnel, excluding sponsor 
personnel involved in data collection or data management.
In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is clo sed.
If the randomization code is broken by [CONTACT_373418] -site personnel, the subject 
must discontinue further study  vaccine administration and must be followed as appropriate (see 
Section 10.2 for details). If the randomization code is broken by [CONTACT_576673] y reporting 
purposes, the subject should not discontinue further study  vaccine administration and may 
remain in the study (if the randomization code is still blinded to the study -site personnel and the 
subject).
6. DOSA GE A ND A DMINISTR ATION
Ad26.RSV.preF (JNJ-64400141) will be supplied in single -use vials. Volumes of 0.5mL 
(1x1011vp) for adults and 0.25 mL (5x1010vp) fortoddlers will be used for intramuscular 
injection.
Placebo will be supplied as sterile 0.9% saline for injection .
An unblinded pharmacist, or other qualified individual will prepare the appropriate vial and 
syringe and provide the syringe in a blinded manner to the study  vaccine administrator who will 
perform the injection. 
                                                
aTo preserve the blind at the subject level, dummy subject identification numbers will be used to link the data to the 
randomization codes. The results of this analysis will only be distributed to sponsor personnel not directly involved in data
collection and data management.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
60
Approved , Date: 18 April 2019Note : the unblinded pharmacist, or other qualified individual, may also perform the 
administration, but will have no other stud y function from randomization onwards. 
Further details o n study vaccine preparation will be provided in the Investigational Product 
Preparation Instructions.
For adult subjects, injections should be administered in the deltoid. For pediatric subjects, 
injections should be administered in the anterolateral aspect of the thigh. Alternating injection 
sites will be used for the vaccinations on Day  1 and Day  29.
7. STUDY V ACCINE COMPLIA NCE
Study  vaccine will be administered intramuscularly  by a study vaccine administrator –a trained 
and qualified study  nurse, medi cal doctor, or otherwise qualified health care professional. The 
date and time of each study  vaccine administration will be recorded in the eCRF.
8. PRE-STUDY AND CONCOMIT ANT THER APY
Pre-study therapi[INVESTIGATOR_43710] 30daysbefore the first dose of study vaccine must be 
recorded in the eCRF during screening.
Concomitant therapi[INVESTIGATOR_780106] 28 days after each vaccination, and additionally  outside of these periods 
when associ ated with an SAE meeting the criteria outlined in Section 12.3.2 .Information on 
concomitant use of herbal supplements or vitamins will not be colle cted.
Use of any experimental medication (including experimental vaccines other than the study  
vaccine) during the stud y is not allowed.
Subjects can receive medications such as acetaminophen, non-steroidal anti-inflammatory  drugs 
(NSAIDs), or antihistamin es as needed, although their use must be documented and use of these 
medications as routine prophy laxis prior to study  vaccination is discouraged, unless if specified 
by [CONTACT_456]. (Note : The use of EMLA®Cream [2.5% lidocaine and 2.5% prilocaine] as a 
topi[INVESTIGATOR_780107] .)
For adult subjects : chronic (longer than 10 days) or recurrent use of systemic corticosteroids 
is prohibited during the study and within [ADDRESS_1072319] administration of study  vaccine 
(Note : ocular, topi[INVESTIGATOR_327865]). Antineoplastic and immunomodulating 
agents or radiotherap y are prohibited in the 6 months prior to screening and during the stud y.
For pediatric subjects :chronic or recurrent use of immunomodulators/suppressors, eg, cancer 
chemotherapeutic agents, oral or parenteral corticosteroids for at least [ADDRESS_1072320], the sponsor should be contact[INVESTIGATOR_530].
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
61
Approved , Date: 18 April 2019Vaccination with live attenuated vaccines within 28 days of a study  vaccination (ie, before and 
after) is prohibited. Other licensed vaccines (ie, not live) should be given at least [ADDRESS_1072321]-exposure 
setting (eg, rabies or tetanus), it must take priority over the study  vaccine.
For pediatric subjects :planning for routine childhood vaccinations will be available from the 
site to ensure that these can be taken at appropriate times during the study .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
Evaluation of the safety /tolerability  of the vaccine regimens will include physical assessment by 
[CONTACT_3449] -site personnel, and subject reports on signs and symptoms following vaccinations. 
Additional visits may be required if in the investigator’s opi[INVESTIGATOR_1649], further clinical or laboratory 
evaluation is needed.
Each Cohort [ADDRESS_1072322] ’s parents/legal guardian or caregiver will be 
provided with a thermometer, ruler, and subject diary  to measure and record body  temperature 
and solicited local (at injection site) and s ystemic events.
The diary  includes instructions how to capture the data and grading scales to assess severit y of 
the sy mptoms. Study staff areresponsible for providing appropriate training for diary  completion 
to avoid missing or incorrect data. The diary  will be reviewe d by [CONTACT_780163] .
For Cohort 0, at each visit/telephone call, each adult subject should be informed that, in the event 
of developi[INVESTIGATOR_007] a combination of s ymptoms of respi[INVESTIGATOR_76099] (persistent [>48 hours] clinical 
symptoms of rhinitis [sneezing or runny nose or congestion] and persistence [>24 hours] of one 
or more of the following: cough, abnormal breathing, fever, lethargy  or decreased appetite), they 
should contact [CONTACT_3433] e site as soon as possible.
For Cohort 1 only, at each visit/telephone call, each subject’s parents/legal guardian or caregiver 
should be informed that, in the event that their child develops a combination of symptoms of 
respi[INVESTIGATOR_23739] (persistent [>48 hours] clinical symptoms of rhinitis [sneezing or runny 
nose or congestion] and persistence [>24 hours] of one or more of the following: cough, 
abnormal breathing, fever, lethargy  or decreased appetite ), they  should contact [CONTACT_780164] .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
62
Approved , Date: [ADDRESS_1072323] in Cohort 1 over approximately 
36weeks from screening will be approximately  14.5 mL .
9.1.2. Visit Windows
For the following visits, windows will be allowe d as indicated:
Second vaccination: ± 3 day s (both cohorts)
[ADDRESS_1072324] -vaccination safet y onl y visit :± 1 day
[ADDRESS_1072325] -vaccination safet y onl y visit: ± 2 days
[ADDRESS_1072326] -final vaccination safety and immunogenicity  visit :± 3 day s
[ADDRESS_1072327] -final vaccination safet y and immunogenicity  visit : ± 14 day s
[ADDRESS_1072328] vaccination safet y follow- up telephone call : ± 14 day s
9.1.3. Screening and Study  Visits –Cohort 0 (Adults)
[IP_ADDRESS]. Screening Phase : Days –28to 1
Only  health y subjects without acute illness or fever and comply ing with the inclusion and 
exclusion criteria specified in Section 4.1.1 andSection 4.2.1 , respectivel y,will be included into 
the study . The investigator will provide detailed information on the study  to the subjects and will 
obtain written informed consent prior to each subjec t’s participation in the study . All the 
procedures described in the Time and Events Schedule will only take place after written 
informed consent has been obtained.
The following evaluations will be performed to determine eligibilit y requirements as specified in 
the inclusion and exclusion criteria:
Physical examination including vital signs measurement (systolic and diastolic blood 
pressure, respi[INVESTIGATOR_2842], heart rate and body temperature) and height and weight
Demographic informa tion
Medical history
Review of pre -study  medications
Review of inclusion/exclusion criteria
Serology  testing (HIV t ype 1 or type 2, hepatitis B, hepatitis C)
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
63
Approved , Date: 18 April 2019Blood sampling for hematology  and biochemistry  laboratory  testing
Women of childbearing potential: serum β -hCG pregnancy  testing
General eligibility  for this clinical study  will be dependent on results of laboratory  tests and the 
medical assessment. Study  subjects who qualify for inclusion based on the medical history , 
physical examination, and laborat ory results will be contact[CONTACT_780165] (Visit 2) within 28days. If necessary , the screening visit may be split into 
several visits.
Subjects with laboratory values not meeting eligibility  criteria at the screening visit may have 
one repeat testing at the discretion of the investigator if the abnormality  is not clinically 
significant and may be a testing aberrancy . Enrollment of a subject with laboratory  values 
representing toxicity  Grades 1 or 2 is allowed if the investigator considers the values not to be 
clinically  significant and reasonable for the population under study . Details on toxicity  grade 
assessment are provided in Section [IP_ADDRESS] .
After laboratory  data, medical history  and physical examination data have been reviewed for 
completeness and adherence to inclusion and exclusion criteria, the subject can be deemed 
eligible for the study .
Unsolicited AEs will be recorded on the AE page of the eCRF from the signing of the ICF until 
[ADDRESS_1072329] dose .
[IP_ADDRESS]. Active Phase – Day 1 to Day  211
[IP_ADDRESS].1. Vaccination (Day s 1 and 29)
Visit 2: Day 1/Day of Randomization/Vaccination 1
After re-check of inclusion and exclusion criteriaa, abbreviated physical examination (at the 
discretion of the investigator) and measurement of vital signs, eligible subjects will be 
randomized as described in Section 5. If medical status and/or physical examination suggest 
significant changes have occurred since screening , the laboratory  tests will be repeated and the 
Day [ADDRESS_1072330] excluded from the study  if he/she fails to meet the 
inclusion and exclusion criteria . Pre-dose samples for baseline immunogenicity  assessments as 
well as pre -dose samples for safet y laboratory  testing (hematology  and biochemistry )and a nasal 
turbinate sample for immunogenicit y assessment will be collected. All women must have a 
negative urine pregnancy test pre-dose. Before the first vaccination, the investigator must check 
for any symptoms of an acute illness or body  temperature ≥38.0 °C. In such a situation, the 
                                                
aTo include exclusion criteria 1, 4, 8, 9, 10, 11, 15, 16 and 17.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
64
Approved , Date: [ADDRESS_1072331] -vaccination.
Visit 5: Day 29/ Vaccination 2
Verification of selected eligibility  criteria,b,cabbreviated physical examination (at the discretion 
of the investigator) and measurement of vital signs will be performed for all subjects 
pre-vaccination. Pre-dose samples for immunogenicity  assessments as well as a nasal turbinate 
sample for immunogenicity  assessment will be collected. All women must have a negative urine 
pregnancy  test pre-dose. Before the second vaccination, the investigator must check for any 
symptoms of an acute illness or body temperature ≥38.0 °C. In such a situation, the subject may 
be vaccinated up to, and no later than [ADDRESS_1072332] -vaccination .
                                                
aIf within the screening window. Otherwise, rescreening is required.
bTo include fever and any acute illness that precludes vaccination; also receipt of any routine i mmunizations.
cTo include exclusion criteria 1, 4, 8, 9, 10, 11, 15, 16 and 17.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
65
Approved , Date: 18 April [ZIP_CODE].[IP_ADDRESS]. Post -first Vaccination Follow -Up
Sentinel S ubjects: [ADDRESS_1072333] safety  information (solicited and unsolicited AEs, SAEs and concomitant medications).
Visits 3 and4 (3and7 Days P ost-first V accination)
Visit [ADDRESS_1072334] 
safet y information (solicited and unsolicited AEs, SAEs and concomitant medications).
Visit [ADDRESS_1072335]-vaccination will include an abbreviated physical examination (at the 
discretion of the investigator), vital signs measurement, and recording of any AEs/SAEs and 
concomitant medications. Samples for safety  laboratory  testing (hematology  and biochemistry ) 
and a nasal turbinate sample for immunogenicity assessment willbe collected . The subject diary 
will be reviewed and collected. If Visit 4 occurs before the end of Day  8 (ie, before the end of the 
post-vaccination diary  period), review of the diary  will still take place, but the diary will be 
returned b y the subject a t Visit 5.
Note : If any of the 12Cohort 0 subjects come in earlier than Day 8 for Visit 4 (allowed window 
is ±2 days), a subsequent phone call will be made at the end of the diary  period to collect diary 
card information recorded between the actual visit and the end of the diary  period on Day  8.
[IP_ADDRESS].3. Post -second Vaccination Follow -Up
Sentinel S ubjects: [ADDRESS_1072336] safety information (solicited and unsolicited AEs, SAEs and concomitant medications).
Post-second V accination: Visits 6 and 7([ADDRESS_1072337]-second V accination)
Visit 6 at 7 days after the second vaccination will include an abbreviated physical examination 
(at the discretion of the investigator), vital signs measurement, and recording of any AEs/SAEs 
and concomitant medications. The subject diary  will be reviewed and collected. If Visit [ADDRESS_1072338] at Visit 7.
Visit 7 at 28 days after the second vaccination will include an abbreviated physical examination 
(at the discretion of the investigator), vital signs measurement (at the discretion of the 
investigator) , recording of any unsolicited AEs/SAEs and concomitant medications. Blood 
samples for immunogenicity  assessments, as well as a nasal turbinate sample for 
immunogenicit y assessment will be collected .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
66
Approved , Date: 18 April [ZIP_CODE].[IP_ADDRESS]. Final Visit – 6Months A fter the Second Vaccination
Visit 8 at 6 months after the second vaccination will include an abbreviated phy sical examination 
(at the discretion of the investigator), vital signs measurement (at the discretion of the 
investigator) , recording of any SAEs and associated concomitant medications. Blood samples 
will be collected for immunogenicity  assessments .
[IP_ADDRESS].5. Early  Withdrawal –Early  Exit Visit
For those subjects who are unable to continue participation in the study , but who do not 
withdraw consent, an early  exit visit will be conducted as soon as possible. In the event of early 
withdrawal from the study , all procedures required at the final visit (Section [IP_ADDRESS].4 ) will be 
performed. Samples for safet y laboratory  testing (hematology  and biochemistry ) will only be 
collected if the early  exit is within 7days of the first vaccination. S amples for immunogenicit y 
assessments will only be collected if the early exit is at least [ADDRESS_1072339] vaccination, solicited AEs will be recorded; 
if the early exit visit occurs within [ADDRESS_1072340] vaccination, unsolicited AEs will be 
recorded.
[IP_ADDRESS]. Safety  Follow -up P hase: Cohort 0 –After Day  [ADDRESS_1072341] one dose of study  vaccine.
9.1.4. Screening and Study  Visits –Cohort 1 (Seropositive Toddlers)
Note : It is possible for any visit for a pediatric subject to be conducted in the subject’s home if 
the study  site has an established standard operating procedure as such. However, at least [ADDRESS_1072342] 
completed Visit 3 with no safet y concerns before moving to vaccination of study  subjects in a 
non-clinic setting (safety information of the first 5 active toddlers will be monitored by [CONTACT_1600](s)/SRP(s) through Visit 3, and escalated to the IDMC in the event of a safet y signal).
[IP_ADDRESS]. Screening Phase: Days –[ADDRESS_1072343] ’s
parent/legal guardian and will obtain his/her written informed consent prior to each subject’s 
participation in the study . All the procedures described in the Time and Events Schedule will 
only take place after written informed consent has bee n obtained.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
67
Approved , Date: 18 April 2019The following evaluations will be performed to determine eligibility  requirements as specified in 
the inclusion and exclusion criteria:
Physical examination including vital signs measurement (respi[INVESTIGATOR_2842], heart rate, body 
temperature) and height and weight
Demographic information
Medical history
Review of pre -study  medications
Review of inclusion/exclusion criteria
Blood sample for immunogenicity  testing*
Blood sample for RSV antibody  testing **
*Collection of blood samples for immunogenicit y assessments can be either at screening, or pre -
dose on Day  1 at the discretion of the investigator. 
**0.5 mL of blood for serostatus assessment can be collected at screening by [CONTACT_780166], at the discretion of the investigator. If 0.5 mL is collected at screening, the 
baseline blood draw for immunogenicit y should be on Day 1.
RSV seropositivity  of Cohort 1 subjects will be assessed by [CONTACT_780167]. Note : RSV -seropositive toddlers may be recruited if RSV seropositivity  was 
assessed via either of these assay s in a different study of the sponsor .In the event that a subject is 
not able to be randomized during the 42-day screening period, eg, due to illness or other 
circumstances, a subject may be rescreened and reconsented. However, a new serostatus blood 
sample would not be needed if the previous sample was deemed seropositive.
General eligibility  for this clinical study  will be dependent on results of the medical assessment. 
Study  subjects who qualify  for inclusion based on the medical history andphysical examination 
will be scheduled for enrollment and first vaccination (Visit 2) within [ADDRESS_1072344] vaccination and from the second vaccination through the following 
28days, together with information about any concomitant medications. SAEs (and any 
associated concomitant medications) will be collected from ICF signature [CONTACT_10782] 1year after 
the first dose.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
68
Approved , Date: 18 April [ZIP_CODE].1.4.2. Active Phase –Day 1 to Day  211
[IP_ADDRESS].1. Vaccination (Day s 1and 29 )
Visit 2: Day 1/Day of Randomization/Vaccination 1
After re-check of inclusion and exclusion criteria,aabbreviated physical examination (at the 
discretion of the investigator) and measurement of vital signs , body  height and weight , eligible 
subjects will be randomized as described in Section 5. If medical status and/or physical 
examination suggests significant changes have occurred since screening, either the Day [ADDRESS_1072345] excluded from the study  if he/she fails to meet the inclusion 
and exclusion criteria . Before the first vaccination, the investigator must check for any  symptoms 
of an acute illness or body temperature ≥38.0 °C. I n such a situation, the subject may beenrolled 
at a later dateb, or be withdrawn at the discretion of the investigator and after consultation with 
the sponsor.
Collection of blood samples for immunogenicity assessments can be either at screening, or pre-
dose on Day [ADDRESS_1072346] -vaccination.
Visit 5: Day 29/Vaccination 2
After verification of selected eligibility  criteria,cabbreviated physical examination (at the 
discretion of the investigator) and measurement of vital signs , body  height and weight will be 
performed for all subjects pre-vaccination. Pre-dose samples for immunogenicity  assessments
will be collected. Before the second vaccination, the investigator must check for any symptoms 
of an acute illness. In such a situation, the subject may be vaccinated up to, and no later than 10 
days after the scheduled vaccination, or be withdrawn at the discretion of the investigator and 
after consultation with the sponsor .In the event of an ongoing AE or other situation precluding 
                                                
aExclusion criterion 21, 22, 25, 26, 28, and 32.
bIf within the screening window. Otherwise, rescreening is required.
cExclusion criterion 21, 22, 25, 26, 28 and 32.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
69
Approved , Date: [ADDRESS_1072347]- vaccination. 
[IP_ADDRESS].2. Post -first Vaccination F ollow -Up
Sentinel S ubjects: [ADDRESS_1072348] vaccination, a telephone call will be made to the parent/legal guardian 
or caregiver of sentinel subjects only  to collect safety  information (solicited and unsolicited AEs, 
SAEs and concomitant medications).
Visits 3 and 4 ([ADDRESS_1072349] V accination)
Visit [ADDRESS_1072350] 
safet y information (solicited and unsolicited AEs, SAEs and concomitant medications).
Visit [ADDRESS_1072351]-vaccination will include an abbreviated physical examination (at the 
discretion of the investigator) ,vital signs measurement, and recording of any AEs/SAEs, 
concomitant medications and RTIs. The subject diary will be reviewed and collected. If Visit 4 
occurs before the end of Day 8 (ie, before the end of the post-vaccination diary  period), review 
of the diary  will still take place, but the diary  will be returned by  [CONTACT_423]’s parent/guardian or 
caregiver at Visit 5.
Note : If any of the first 12 Cohort 1subjects come in earlier than Day 8 for Visit 4 (allowed 
window is ±2 days), a subsequent phone call will be made at the end of the diary  period to 
collect diary  card information recorded between the actual visit and the end of the diary  period 
on Day  8.
[IP_ADDRESS].3. Post -second Vaccination Follow -Up
Sentinel S ubjects: [ADDRESS_1072352]-second V accination
At 48 hours after the second vaccination, a telephone call will be made to the parent/legal 
guardian or caregiver of sentinel subjects only to collect safety  information (solicited and 
unsolicited AEs, SAEs and concomitant medications).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
70
Approved , Date: [ADDRESS_1072353]-second V accination: Visits 6, 7, 8 and 9 (3, [ADDRESS_1072354]-second 
Vaccination)
Visit [ADDRESS_1072355] 
safet y information (solicited and unsolicited AEs, SAEs and concomitant medica tions).
Visit 7 at 7 days after the second vaccination will include an abbreviated physical examination 
(at the discretion of the investigator), vital signs measurement, and recording of any AEs/SAEs, 
concomitant medications and RTIs. The subject diary  will be reviewed and collected. If Visit [ADDRESS_1072356]’s parent/guardian or caregiver at 
Visit 8.
Visit 8 at 28 days after the second vaccination will include an abbreviated physical examination 
(at the discretion of the investigator), vital signs measurement (at the discretion of the 
investigator) , measurement of body  height and weight, recording of any unsolicited AEs/SAEs, 
concomitant medications, and RTIs. Blood samples will be collected for immunogenicit y 
assessments .
Visit 9 at 6 months after the second vaccination will include an abbreviated phy sical examination 
(at the discretion of the investigator), vital signs measurement (at the discretion of the 
investigator) , measurement of body  height and weight, recording of any SAEs and associated
concomitant medications, and RTIs. Blood samples will be collected for immunogenicit y 
assessments .Visit 9 (Day 211) will be the final visit of theactive phase for Cohort 1 subjects .
Note : If Visit [ADDRESS_1072357] safet y information.
[IP_ADDRESS].4. Early  Withdrawal –Early  Exit Visit
For those subjects who are unable to continue participation in the study  up to Day 211, but for 
whom consent is not withdrawn, an early exit visit will be conducted as soon as possible . In the 
event of early  withdrawal from the study , all procedures requi red at Visit 9 (Section [IP_ADDRESS].3 ) 
will be performed. Samples for immunogenicit y assessments will be collected at the early exit 
visit as follows: if the early  exit visit is before Day 29, 4 mL for cellular assessments and 1 mL 
for humoral assessments will be collected; if the early exit visit is after Day 29, onl y [ADDRESS_1072358] vaccination, solicited AEs will be recorded; 
if the early exit visit occurs within [ADDRESS_1072359] vaccination, unsolicited AEs will be 
recorded.
[IP_ADDRESS]. Safety  Follow -up Phase : Cohort 1 –After Day  [ADDRESS_1072360]’s parent/legal guardian or caregiver will be contact[CONTACT_528609] (or clinic 
visit) through 1year after the first dose, including during the active phase and safet y follow -up 
phase (every  30 days ± 7 days outside theRSV season, but every  14 days ± 3 days in season) .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
71
Approved , Date: [ADDRESS_1072361]-vaccination period, calls will remind parents/legal guardians to contact 
[CONTACT_780168]. During the RSV season, but outside the 28-day 
post-vaccination period, calls will remind parents/legal guardians to contact [CONTACT_780169] a combination of symptoms of respi[INVESTIGATOR_23739] (persistent [>48 hours] 
clinical symptoms of rhinitis [sneezing or runny  nose or congestion] and persistence [>24 hours] 
of one or more of the following: cough, abnormal breathing, fever, lethargy  or decreased 
appetite ). These calls will also check for SAEs and associated concomitant medications, any 
MA-RTIs or severe LRTIs, and any subsequent medical care that may have been sought, since 
the previous visit or telephone contact (includes contacts with subjects who received at least one 
dose of study  vaccine but withdrew from further dosing).
The follow -up phase will include all subjects who received at least one dose of study  vaccine.
9.2. Study Evaluations
9.2.1. Immunogenicity
Venous blood samples will be collected for the determination of humoral and cellular responses, 
respectivel y, according to the Time and Events Schedules . Sample collection and processing will 
be performed by [CONTACT_780170].
Humoral and cellular immunogenicit y evaluations are summarized in Table 6and Table 7, 
respectivel y.
Table 6: Summary of Immunogenicity Assays (Hum oral)
Assay Purpose
Secondary en dpoints
RSV neutralization A Analysis of neutralizing antibodies to the Astrain
F-protein antibody
(ELISA; pre- and/or post -fusion) Analysis of antibodies binding to RSV F protein in post -fusion and/or pre-
fusion form
Exploratory endpoints
RSV strain cross -neutralization Analysis of cross -neutralizing antibodies to B and/or a different A strain(s)
F-protein antibody specificity 
characterization Pre-and post -F specificity by [CONTACT_624661], 
and/or competition ELISA. Adsorption of serum or plasma with pre -F and 
post-F protein before any antibody assay, epi[INVESTIGATOR_111050], functional 
VNA
Adenovirus neutralization assay Analysis of neutralizing antibodies to adenovirus
Functional and molecular 
antibody characterizationAnalysis of antibody characteristics including ADCC, ADCP, avidity, Fc 
characteristics, Ig isotype, functional VNA and protective antibody 
assessments
ADCC = antibody -dependent cell-mediated cytotoxicity; ADCP = antibody -dependent cellular phagocytosis; ELISA = enzyme -
linked immunosorbent assay; F = fusion; Ig = immunoglobulin; RSV = respi[INVESTIGATOR_4345]; VNA = virus neutralizing 
antibod y
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
72
Approved , Date: 18 April 2019Table 7: Summary of Immunogenicity Assays (Cellular)
Assay Purpose
Secondary endpoints
Flow  cytom etry (ICS)* Analysis of T -cell responses to RSV F -protein peptides for Th1/Th2 subtypi[INVESTIGATOR_780094]γ ELISpot T-cell IFNγ responses to RSV F -protein peptides
ICSAnalysis of T -cell responses to RSV F-protein peptide -stimulated PBMC s
(including but not limited to, CD4/CD8, IL2, INFγ, TNFα , activation markers and 
memory)
Cytokine analysisAnalysis of secreted cytokines in RSV F peptide -stimulated PBMC supernatant, 
including, but not limited to, measurement of Th1/Th2 cytokine balance
ELISpot = enzyme -linked immunospot; F = fusion; ICS = intracellular cytokine staining; IFNγ = interferon gamma; IL = 
interleukin; PBMC = peripheral blood mononuclear cell; Th = T-helper (cell); RSV = respi[INVESTIGATOR_4345]; TNFα = tumor 
necro sis factor alpha
* Cytokine analysis for Th1/Th2 profiling will be done in cases where no ICS data can be generated due to insufficient number of 
PBMCs for ICS assay
In addition to RT-PCR performed on a nasal turbinate sample collected at the time of infec tion, 
any immunogenicit y blood sample collected from any Cohort [ADDRESS_1072362] who subsequentl y 
develops a suspected RTI may also be assay ed by a serological assay  (eg, ELISA specific to 
RSV protein G and/or N) to confirm RSV infection.
For adults, nasal turbin ate samples , collected pre-dose on Days [ADDRESS_1072363]-Dose 1 
(Day  8) and [ADDRESS_1072364]-Dose 2 (Day  57) will be used to assess any Ig or cellular immune 
component.
Instructions for the collection, handling, storage, and shipment of blood and nasal turbinate
sample s for immunogenicity  assay are found in the Laboratory Manual that will be provided. 
Collection, handling, storage, and shipment of blood and nasal turbinate samples to the central 
laboratory  must be under the specified, and where applicable, controlled temperature conditions 
as indicated in the Laboratory  Manual.
9.2.2. Other Evaluations –RSV Infection
RSV seropositivity  of Cohort 1 subjects will be assessed by [CONTACT_780171]. The cut-off for seropositivity  by [CONTACT_780141] a titer >10EIA units and the cut-off 
by [CONTACT_780172] a titer >4.Note : RSV -seropositive toddlers may be recruited if 
RSV seropositivity  was assessed via either of these assay s in a different study of the sponsor .
Nasal turbinate samples , taken from any Cohort [ADDRESS_1072365] with a combination of respi[INVESTIGATOR_780108] (but outside of the 28-da y post-vaccination period) , and from any 
Cohort [ADDRESS_1072366] be recorded in the eCRF or laboratory  requisition form.
                                                
aPersistent (>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and persistence (>24 hours) of one 
or more of the following: cough, abnormal breathing, fever, lethargy or decreased appetite.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
73
Approved , Date: [ADDRESS_1072367] refers to adult subjects or the parent/legal 
guardian for pediatric subjects.
Any clinicall y relevant changes occurring from ICF signature [INVESTIGATOR_107990] [ADDRESS_1072368] 
be recorded on the eCRF. Any clinicall y significant abnormalities, including those persisting at 
the end of the study /early  withdrawal, will be followed by [CONTACT_439674] a clinically  stable e ndpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the 
timepoints provided in the Time and Events Schedule .
Adverse Events
AEs will be reported by [CONTACT_423] (or, when appropriate, by a  caregiver, surrogate, or the 
subject ’s legall y acceptable representative) . AEswill be followed by  [CONTACT_369023] 12, Adverse Event Reporting.
For solicited AEs, the following applies:
Solicited Adverse Events
Information related to solicited events as defined in Section 12.1.[ADDRESS_1072369] will be provided with a diary  and 
instructions on how to complete the diary (Section 9.1.1 ). There will be a minimum 30-minute 
post-vaccination , or a minimum 60-minute post-vaccination assessment of solicited events at the 
site(accordi ng to local approvals). Diary  information will be transcribed by [CONTACT_780173].
Injection Site (Local) Adverse Events
Each subject will be asked to note in the diary  occurrences of pain/tenderness, ery thema and 
induratio n/swelling at the study  vaccine injection site daily  for [ADDRESS_1072370]-vaccination. The 
extent (largest diameter) of any erythema, and induration/swelling should be measured 
(using the ruler supplied) and recorded daily.Induration/swelling should also be graded 
using the functional scale.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
74
Approved , Date: 18 April 2019oInjection Site Pain/Tenderness
Injection site pain (eg, stinging, burning) is an unpleasant sensory  and emotional 
experience associated with actual or potential tissue damage and occurr ing at the 
immunization site (with or without involvement of surrounding tissue). Injection site 
tenderness is a painful sensation localized at the injection site upon palpation and/or 
movement of the limb. Due to subjective nature of the reaction, the severity assessment 
of pain/tenderness is self-reported (if a subject is unable to provide self-report, other 
reporters incl ude parent/care giver or health care provider ).[ADDRESS_1072371] be described by [CONTACT_667146] .
oInjection Site Swelling/Induration
Injection site swelling is a visible enlargement of an injected limb. It may be either soft 
(typi[INVESTIGATOR_897] ) or firm (less typi[INVESTIGATOR_2855]). Injection site induration is a palpable thickening, 
firmness, or hardening of soft tissue, usuall y has well-demarcated palpable borders, can 
be visible (raised or sunken compared to surrounding skin), is often ‘woody ’ to touch 
and has a flat shape. As differentiation between swelling and induration may be difficult 
without health care professional’s assessment, both symptoms have been combined to 
allow self-assessment by [CONTACT_748]. Both swelling and induration can best be 
described b y looking and measuring .
Note : Any other injection site events not meeting the above case definitions should be 
reported separatel y as unsolicited AE s.23,[ADDRESS_1072372] temperature of that day 
will be used in the eCRF.
Fever is defined as endogenous elevation of body temperature ≥38° C, as recorded in at least 
one measurement.28
                                                
aRecommended orally for adult subjects; rectally or axillary for pediatric subjects (actual routes to be recorded in the eCRF).
bAll Day [ADDRESS_1072373]-vaccination diary assessments, including temperature measurements, may be collected earlier to coincide with 
the corresponding clinic visit.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
75
Approved , Date: [ADDRESS_1072374]-vaccination 
symptoms of the following events: for adult subjects –fatigue, headache, myalgia, arthralgia, 
chills, nausea and fever (ie, body  temperature ≥38°C); for pediatric subjects –loss of 
appetite, vomiting, diarrhea, decreased activity /lethargy , irritability /crying and fever (ie, body 
temperature ≥38°C).
The severit y of these solicited systemic AEs will be graded by [CONTACT_667147] 12.1.[ADDRESS_1072375] symptoms and 
maximum severity  in the diary  after resolution.
[IP_ADDRESS]. Respi[INVESTIGATOR_168002] s
RTIs will be reported as follows:
During the 28 -day period after each vaccination, all RTI s will be repo rted.
During the RSV season, but outside the 28-day period after each vaccination, RTIs will be 
reported for which a combination of respi[INVESTIGATOR_780109].
Outside the RSV season, only MA-RTIs and severe LRTIs will be reported (ie, for the 
whole study  period).
RTIs, preferabl y as a diagnosis, will also be reported on the AE page of the eCRF if they occur 
within 28 days following vaccination. Any RTI fulfilling the criteria of an SAE would be 
reported as such during the entire study .Any severe LRTI will be reported using the SAE 
reporting s ystem and SAE form, regardless of whether the event fulfills the criteria of an SAE.
[IP_ADDRESS]. Clinical Laboratory  Tests –Cohort 0 Only
Blood samples for serum chemistry  and hematology  will be collected at screening, 
pre-vaccination on Day 1 and on Day 8. The following tests will be performed by a local
laboratory  (*parameters only  measured at screening):
Hematology Panel
hemoglobin
white blood cell (WBC) count with differential
platelet count
prothrombin time*
activated partial thromboplastin time*
fibrinogen*
                                                
aPersistent (>48 hours) clinical symptoms of rhinitis (sneezing or runny nose or congestion) and persistence (>24 hours) of one 
or more of the following: cough, abnormal breathing, fever, lethargy or decreased appetite.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
76
Approved , Date: 18 April 2019Biochemistry Panel
Review and Grading of Laboratory Data
The investigator must review each laboratory  result, document this review and assess 
systematically  any clinical significance. The laboratory  reports must be filed with the source 
documents.
Laboratory  values will be initially  evaluated by [CONTACT_780174]. Abnormal values outside the local laboratory  range of normal will be graded according 
to the FDA Guidance document “Toxicity  Grading Scale from Health y Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials” (see Attachment 1). Laborator y 
values within local laboratory normal limits will not be FDA graded and will be considered as 
normal.
Reporting Laboratory Abnormalities as AEs
Any clinically  significant abnor mal laboratory  value within [ADDRESS_1072376]-vaccination that falls 
outside of the local laboratory normal range and that requires follow -up will be captured as an 
AE. Laboratory  values outside normal ranges that are not clinicall y significant in the judgment of 
the investigator, should not be recorded as AEs.
Any laboratory  value falling within the local laboratory normal range will not be severity  graded 
or recorded as an AE, regardless of whether the value falls within FDA ranges for Grade 1 or 
higher.
Note : Values for parameters falling within the local laboratory  normal range should not be 
reported as AEs.
Repeat of Clinically Significant Laboratory Tests
For an y clinicall y significant abnormal laboratory value that has increased in grade over baseline, 
the test must be repeated at the next scheduled visit or sooner based on the investigator’s 
judgment , however Grade 3 abnormalities should be retested withi n 48 hours. Any clinically 
significant abnormalities (including those persisting at the end of the study  or at early 
withdrawal) will be followed by [CONTACT_43727] a clinically  stable 
endpoint is reached (see Section 12.3).      sodium
      potassium
      creatinine
      blood urea nitrogen 
      aspartate aminotransferase (AST)
      alanine aminotransferase (ALT)
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
77
Approved , Date: [ADDRESS_1072377] with laboratory  values outside of the local
laboratory normal range representing FDA toxicity  Grade 1 is allowed if the investigator 
considers the values reasonable for the population under study and not clinically significant.
Additional Clinical Laboratory Assessments
Additional clinical laboratory  assessments ( HIV type 1 or type 2, hepatitis B, hepatitis C 
serology )will be performed locally at screening for Cohort 0 only .
[IP_ADDRESS]. Vital Signs
Blood pressure (Cohort 0 only )and pulse/hear t rate measurements should be preceded by  [CONTACT_2669] 
[ADDRESS_1072378] in a quiet setting without distractions (eg, television, cell phones):
Heart rate (beats per minutes, bpm), respi[INVESTIGATOR_697] (breaths per minute), systolic blood 
pressure (mmHg) and diast olic blood pressure (mmHg)
Body temperature (oral route recommended for Cohort 0, rectal or axillary route 
recommended for Cohort 1)
Confirmatory  vital signs measurement can be performed if inconsistent with a prior 
measurement. If any clinically  significant changes in vital signs are noted, they will be reported 
as AEs and followed to resolution, or until reaching a clinically  stable endpoint.
[IP_ADDRESS]. Physical Examination
Full physical examination, including length /height and body  weight, will be carried out at 
screening. At all other visits, an abbreviated, symptom -directed examination will be performed 
by [CONTACT_780175] y relevant issues, clinically  relevant symptoms and 
medical history . Symptom -directed physical examination may be repeated if deemed necessary  
by [CONTACT_093].
Note : For Cohort 0, phy sical examination will only  be required at the screening visit.
Physical examinations will be performed by [CONTACT_780176] . 
Any abnormalities or changes in severit y noted during the review of body  systems should be 
documented in the eCRF.
10. SUBJECT COMPLETION/ DISCONTINUA TION OF STUDY VACCINE / 
WITHDRA WALFROM THE STUDY
10.1. Completion
A subject will be considered to have completed study  vaccination if he or she has received all 
study vaccinations. A subject will be considered to have completed the study  if he or she has 
completed assessments through to the end of the study  (see Section 17.9.1 ).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
78
Approved , Date: 18 April 201910.2. Discontinuation of Study Vaccine /Withdrawal from the Study
Discontinuation of Study Vaccine
A subject will not be automatically withdrawn from the study  if they have to discontinue from 
study vaccination before the end of the study  vaccine regimen.
Subjects will be discontinued from study  vaccine administration for the reasons listed below. 
These subjects must not receive any additional dose of study  vaccine but should continue other 
study  procedures, eg, safety  follow -up:
Anaph ylactic reaction following vaccination, not attributable to causes other than 
vaccination
Pregnancy  (Cohort 0 only )
Any related SAE
Any related AE, worsening of health status or intercurrent illness that, in the opi[INVESTIGATOR_1070], requires study  vaccine discontinuation
Withdrawal from the Study
Each subject has the right to withdraw ( Cohort 1 : “subject’s parent/legal guardian has the right to 
withdraw their child” ) from the study  at any time for any reason without affecting the right to 
treatment by [CONTACT_093]. Although the subject (Cohort 1: “subject’s parent/legal guardian”)
is not obliged to give a reason for withdrawing prematurel y, the investigator should make a 
reasonable effort to ascertain the reason(s) while fully  respecting the subject’s rights.
A subject will be withdrawn from the stud y for any of the following reasons:
Repeated failure to comply  with protocol requirements
Decision b y the sponsor or the investigator to stop or cancel the stud y
Decision by [CONTACT_780177]/Independent Ethics 
Committee (I RB/IEC) to stop or cancel the study
Lost to follow -up
Withdrawal of consent
Death
Any unnecessary  study discontinuation should be avoided. Should a subject be withdrawn, all 
efforts should be made to complete and report the observations as thoroughl y as possible. 
Whenever a subject is withdrawn from the study , independent of the reason, a final evaluation 
should be completed for that subject and the major reason for which the subject was withdrawn 
must be stated. If a subject is lost to follow -up, every  reasonable effort must be made by [CONTACT_10748] -site personnel to contact [CONTACT_23814]/
withdrawal. The measures taken to follow up must be documented.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
79
Approved , Date: [ADDRESS_1072379] withdraw searly  from the study ,assessments for earl y withdrawal should be obtained 
(see Section [IP_ADDRESS].5 andSection [IP_ADDRESS].4 ).
Subject s who wish to withdraw consent from participation in the study  will be offered a single 
exit visit for safet y follow -up (prior to formal withdrawal of consent). They  have the right to 
refuse.
Withdrawal from the Use of Samples in Future Research
The subject may withdraw consent for use of samples for future research (refer to 
Section 16.2.5 ). In such a case, samples will be destroyed after they are no longer needed for the 
clinical study . Details of the sample retention for research are presented in the main I CF.
10.3. Contraindications to Vaccination
The following events constitute a contraindication to vaccination at that point in time:
Severe acute illness at the time of vaccination. This does not include minor illnesses such as 
diarrhea.
Fever (body temperature ≥38.0 °C) at the time of vaccination.
If any of these events occur at the scheduled time for the first vaccination, enrollment at a later 
date is permittedaat the discretion of the investigator and after consultation with the sponsor . If 
any of these events occur at the scheduled time for the second vaccination, the subject may be 
vaccinated up to 10daysbeyond the scheduled vaccination , or be withdrawn from further 
vaccination at the discretion of the investigator and after consultation with the sponsor .In the 
event of an ongoing AE or other situation precluding subject vaccination within 10 day s, subjects 
may be vaccinated bey ond the 10 -day window at the discretion of the sponsor.
Note : Medicall y indicated vaccines should be given at least 14 day s before or 14 day s after study  
vaccine administration (see Section 4.3).
                                                
aIf within the screening window. Otherwise, rescreening is required.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
80
Approved , Date: [ADDRESS_1072380] atistical Analy sis Plan (SAP).
Planned analyses aredescribed in Section 11.8.
11.1. Analysis Sets
The Full Analysis Set (FA) includes all subjects who w ere randomized and received at least one 
dose of study  vaccine, regardless of the occurrence of protocol deviations. Vaccination 
assignment will follow the as -treated principle. All safety  analyses will be based on the FA set.
As a sensitivity  anal ysis, ke y immunogenicit y tables will also be based on the FA set.
The Per-protocol Immunogenicity Set (PPI ) will include all randomized and vaccinated 
subjects for whom immunogenicity  data are available, excluding subject swith major protocol 
deviations expecting to impa ct the immunogenicity  outcomes.
In addition, the following samples will not be included in the PPI  [CONTACT_55866]:
If subjects miss one or more doses, but continue the planned visit schedule, samples taken 
after the planned but missed dose(s) will not be taken into account;
For subjects who experience a natural RSV infection (based on RT-PCR, or other sources), 
samples taken after the natural infection are not be taken into account.
Any subject who receives study  vaccine beyond the Day 29 window specified in the Time 
and Events Schedule would not be included in the per -protocol immunogenicity  analy ses.
The anal ysis of immunogenicity  will be based on the PPI  [CONTACT_55866].
11.2. Sample Size Determination
The number of subjects chosen for this study  will provide a preliminary  safety and 
immu nogenicit y assessment. Placebo recipi[INVESTIGATOR_111072] y purposes 
and will provide additional control specimens for immunogenicit y assa ys.
While mild to moderate vaccine reactions (local site and systemic responses) are expected, AEs 
that preclude further dose administration or more serious ones that would limit product 
development are not anticipated.
The following table shows the probabilities of observing at least one AE at given true AE rates:
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
81
Approved , Date: [ADDRESS_1072381] one AE in N subjects
N=4 N=8 N=12 N=24
0.5% 2% 4% 6% 11%
1% 4% 8% 11% 21%
2.5% 10% 18% 26% 46%
5% 19% 34% 46% 71%
10% 34% 57% 72% 92%
25% 68% 90% 97% 100%
50% 94% 100% 100% 100%
11.3. Criteria for Exploratory  Endpoints
11.3.1. Definitions for Exploratory  Endpoints
The exploratory  endpoints shown below will be collected to assess the feasibility  of, and gain 
expertise in the collection of such events for future studies.
RSV MA -RTI: All subjects with RSV -RTI that is medicall y attended, ie when the
subject’s parent/legal guardian seeks medical attention outside of normal
study  procedures , including health care professional’s visit to the home,
clinic visit, emergency  room attendance, and hospi[INVESTIGATOR_063] . (Note : 
medical attention outside normal study  procedu res will as much as 
possible also be captured on the RSV Sy mptoms Form .)
Severe LRTI: For subjects in Cohort 1, severe RSV -LRTI will be defined as the
presence of severe LRTI as assessed by [CONTACT_15741], and a positive
assessment for RSV.
[IP_ADDRESS]. Presence of Severe LRTI as A ssessed by  [CONTACT_780178][INVESTIGATOR_23715], the CEC will determine the presence or 
absence of severe LRTIs by [CONTACT_780179][INVESTIGATOR_13521] y 
disease, with a special focus on the following characteristics (“WHO” criteria30):
Respi[INVESTIGATOR_780110]
LRTI defined as fast breathing or oxygen saturation ( SpO2) <95%
AND
≥1 of the severe disease feature:
ooximetry  <93%
olower chest wall indrawing
[IP_ADDRESS]. Determination of RSV Positivity
A subject is considered RSV positive if he/she has a positive RT-PCR for RSV on nasal 
turbinate samples (central laboratory ).
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
82
Approved , Date: 18 April 2019If a RT-PCR test result for RSV is missing (ie, not available or not conclusive), the CEC 
will assess RSV positivity using all available clinical and laboratory  information.
11.4. Subject Information
For all subjects, demographic characteristics (eg, age, height, weight, body  mass index [BMI ], 
race, and gende r), and other baseline characteristics (eg, physical examination, medical history , 
and concomitant diseases) will be tabulated and summarized with descriptive statistics. BMI will 
only be calculated for Cohort 0 (adults). For the toddlers, the weight and length percentiles 
according to the WHO pediatric growth and weight charts will be tabulated.7
11.5. Immunogenicity  Analyses
No formal hypothesis on immunogenicit y will be tested. Descriptive statistics (geometric mean 
and 95% confidence interval [CI]for ELISA and virus neutralization assay s; median and 
quartiles for ELISpot and ICS) will be calculated for continuous immunologic parameters at all 
timepoints. Graphical representat ions of immunologic parameters will be made as applicable.
Frequency  tabulations will be calculated for discrete (qualitative) immunologic parameters as 
applicable.
The primary  analysis set for immunogenicit y is the PPI [CONTACT_55866].As a sensitivity  analysis, key tables 
will also be based on the FA set.Depending on their occurrence, the effect of missed doses or 
natural infections might be further explored. Note that they will be included in the tables 
showing the FA set .
11.6. RSV Infection
Incidence of any RSV infecti on,as described in Section 3.2, in Ad26.RSV.preF and placebo 
subjects will be summarized by [CONTACT_9086].
11.7. Safety  Analyses
No formal statistical testing of safety  data is planned. All safety  data will be ana lyzed 
descriptivel y by [INVESTIGATOR_24858].
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_43760] (MedDRA). All reported AEs with onset after 
vaccination up to [ADDRESS_1072382] narratives may be provided, as appropriate, for those 
subjects who die, who discontinue study  vaccine due to an AE, or who experience a severe AEor 
anSAE .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
83
Approved , Date: 18 April 2019Summaries and/orlistings may be provided separatel y for AEs with onset outside the above 
defined timeframe (ie, beyond [ADDRESS_1072383]-vaccination) and that were reported pre-dose at the 
moment of subsequent vaccinations for studies using multiple doses.
Solicited local (at injection site) and sy stemic AEs will be summarized descriptively . The overall 
frequencies per vaccine group as well as frequencies according to severity  and duration will be 
calculated for solicited AEs. In addition, the number and percentages of subjects with at least one 
solicited local (at injection site) or systemic AEwill be presented. Frequencies of unsolicited 
AEs, separatel y for all and vaccination -related only, will be presented by [CONTACT_204595].
Clinical Laboratory Tests (Cohort 0 Only)
Laboratory  abnormalities will be determined according to the FDA Guidance document (see 
Attachment 1), or in accordance with the normal ranges for the clinical laboratory  parameter if 
no grades are available. If a laboratory  value falls within the grading as specified in the FDA 
table, but also within the laboratory  normal limits, the value is considered as normal.
Vital Signs
A tabulation of the distribution of temperatures per half degree intervals will be provided. For 
heart rate and respi[INVESTIGATOR_697], the percentage of subjects with values beyond clinically  relevant 
limits will be summarized.
Physical Examination
Physical examination abnormalities will be listed.
11.8. Planned Analyses
The following anal yses will be performed:
Cohort 0: primary  analysis will be performed when all subjects have reached Day 57 
(28days post-Dose 2) or discontinued earlier. All available safet y and immunogenicit y data 
gathered so far will be included in the anal ysis; unblinded at the group level.
Cohort 1: interim analy sis will be performed when at least [ADDRESS_1072384] reached Day 29 
(28days post-Dose 1) or discontinued earlier. All available safet y and immunogenicit y data 
gathered so far will be included in the anal ysis; unblinded at the group level .
Cohort 1: primary  analysis will be performed when all subjects have reached Day 57 
(28days post-Dose 2) or discontinued earlier. All available safet y and immunogenicit y data 
gathered so far will be included in the anal ysis; unblinded at the group level.
Final analysis of both cohorts ; at the end of the study , 1year after the first dose; unbli nded
Additional interim analyses (blinded or unblinded at the group level) may be performed during 
the study  for the purpose of informing future vaccine -related decisions in a timely  manner, or 
upon health authorit y request. The results will not influence the conduct of the study  in terms of 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
84
Approved , Date: 18 April 2019early termination or later safet y or immunogenicity  endpoint assessments, and will only be 
available to a selected group of sponsor personnel, excluding sponsor personnel involved in data 
collection or data management.
11.9. Data Review Committee s
11.9.1. Independent Data Monitoring Committee (IDMC)
An IDMC will be established to review safet y data, and as needed on an ad hoc basis to ensure 
the continuing safet y of the subjects enrolled in this study . The IDMC will convene to discuss 
any situation that meets a study  vaccination pausing rule (see Section 11.10 ).
The IDMC will also monitor severe LRTI. The presence of severe LRTI will be determined by 
[CONTACT_15741], a separate committee (see Section 11.9.2 ). The o utcome of the adjudication of the CEC 
as well as the determination of RSV positivit y will be provided to the IDMC.
The IDMC will monitor severe LRTI as detailed in the IDMC charter.
The IDMC will consist of members independent of the sponsor, including at least one medical 
expert [INVESTIGATOR_524930]. The IDMC responsibilities, 
authorities, and procedures will be documented in its charter. An external statistician 
independent of the sponsor and not involved in the interim, primary , and final analyses of the 
study  will prepare the data and perform all a nalyses for review by  [CONTACT_31849].
In any case(s)under review, the IDMC will review blinded data first, but is entitled to and has 
the right to require submission of unbl inded data if deemed necessary .
Individual treatment information and other information essential to maintaining the blinded and 
controlled study  design including the detailed results of the IDMC analyses will not be revealed 
to any one outside of the IDMC.
Details on the intervals of the safet y evaluations and on how the integrity  of the study  will be 
maintained when the blind is broken with an IDMC analy sis will be provided in the IDMC 
charter.
Safety  data from the interim and primary  anal yses will be share d with the IDMC.
If any question arises related to safet y, the IDMC will be convened.
11.9.2. Clinical Endpoint Committee (CEC)
The CEC is an independent panel consisting of external medical experts with relevant experience 
in RSV in children. At all times during the study , the CEC will stay blinded, and hence CEC 
members will not be part of the IDMC. Full details of CEC responsibilities, authorities, and 
procedures will be documented in its charter.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
85
Approved , Date: 18 April 2019The presence of severe LRTI  will be determined by [CONTACT_15741]. By [CONTACT_780180], including clinical information from SAE forms related to respi[INVESTIGATOR_82212] , the CEC will decide whether a given situation concerns a severe LRTI. The outcome of 
the adjudication of the CEC, as well as the determination of RSV positivity , will be provided to 
the IDMC .
For subjects with an SAE related to respi[INVESTIGATOR_23715], the CEC will determine the presence or 
absence of severe LRTIs by [CONTACT_780179][INVESTIGATOR_23697], with a special focus on the following characteristics (“WHO” criteria30):
Respi[INVESTIGATOR_780110]
LRTI defined as fast breathing or oxygen saturation ( SpO2) <95%
AND
≥1 of the severe disease feature:
ooximetry  <93%
olower chest wall indrawing
11.10. Study Vaccination Pausing Rules
The PI[INVESTIGATOR_780111]. If study  vaccination is 
considered to raise significant safet y concerns, further vaccination of subjects will be suspended 
until IDMC review is carried out and subsequent communication between the sponsor and the 
investigators takes place.
The occurrence of any of the following events will lead to suspension of further study 
vaccination, and trigger a meeting of the IDMC to discuss study  suspension, adaptation or 
discontinuation of further vaccination :
1.One or more subjects in the same cohort experience an SAE or other potentially 
life-threatening (Grade 4) event that is determined to be related to stud y vaccine; OR
2.One or more subjects in the same cohort experience anaph ylaxis clearly not attributable to 
other causes than vaccination with study  vaccine; OR
3.Two or more subjects in the same cohort experience a Grade 3or 4unsolicited AE of the 
same ty pe, determined to be related to study  vaccine, that persists for 72 hours or longer; OR
4.Two or more subjects in the same cohort experience a Grade 3 or 4 solicited sy stemic AE of 
the same ty pe, determined to be related to study  vaccine, that persists for 72 hours or longer; 
OR
5.Two or more subjects in Cohort 0 experience a persistent (upon repeat testing) Grade 3 or 4 
laboratory  abnormalit y related to the same laboratory  parameter and considered related to 
study  vaccine, that persists for 72 hours or longer; OR
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
86
Approved , Date: [ADDRESS_1072385], regardless o f causality .
Note : The count of subjects for each pausing rule will be across all study sites. After the first 
IDMC meeting triggered by [CONTACT_172719] a given pausing rule, the IDMC will convene 
thereafter for each additional subject meeting that pausing rule.
To enable prompt response to a situation that would trigger pausing rules 3 or 4, the investigator 
should update the eCRF with information on any  Grade 3 or 4 AE on the same day  that the AE is 
reported.
If any of the above specific pausing rules are met, the IDMC will make recommendations 
regarding the continuation of the study  to the sponsor. Study  suspensions or terminations will 
occur within 5 working day s after the decision is made, unless local regulations specify  a shorter 
timeframe. Local regulatory  authorities including IECs/I RBs will be informed within the 
appropriate regulatory -mandated timeframes. A study  may be resumed only upon approval of a 
substantial amendment to the initial study  application by [CONTACT_780181]/IRBs. The sponsor will communicate conclusions regarding study  continuation to the 
investigators, the IECs/I RBs and the national regulatory  authorities as appropriate.
Vaccinations for an individual subject may be suspended for safety  concerns other than those 
described above, at the discretion of the investigator if he/she feels the subject’s safet y may be 
threatened. The investigator may ask for a review meeting to be held for any single event or 
combination of multiple events which, in his/her professional opi[INVESTIGATOR_1649], jeopardize the safet y of 
the subjects or the reliability  of the data.
Vaccinations for the study  may be suspended for safet y concerns other than those described 
above or before pausing rules are met if, in the judgment of investigator, subject safet y may be 
threatened. The sponsor should be notified that the IDMC will need to be convened.
Central randomization will be implemented in this study . Central randomization ensures that 
study  recruitment and dosing can be effectivel y halted simultaneously  across all sites in the event 
of a situation meeting any of the pausing rules. Sponsor activities and responsibilities related to 
temporary  study suspension and restart are described in the Sponsor’s applicable standard 
operating procedures ( SOPs).19,[ADDRESS_1072386] operating procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765] .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
87
Approved , Date: [ADDRESS_1072387] ing these events is specified.
Solicited Adverse Events
Solicited AEs are pre-defined local (at the injection site) and systemic events for which subject s 
are specificall y questioned and which are noted by [CONTACT_780182](see Section 9.1.1 , 
Overview).
Unsolicited Adverse Events
Unsolicited AEs are all AEs for which subjects arespecifically  not questioned in the subject 
diary .
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with study  vaccine . An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investigational or non-investigational) product (Definition per International 
Conference on Harmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline cond ition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note : The sponsor collects unsolicited AEs starting with the signing of the ICF for [ADDRESS_1072388]- vaccination (refer to 
Section 12.3.[ADDRESS_1072389] AE recording). For both cohorts, all SAEs 
will be collected from ICF signature [CONTACT_780192] . RTIs, preferably  as a diagnosis, will 
be reported on the AE page of the eCRF if they occur within 28 days following vaccination ; any 
RTI fulfilling the criteria of an SAE would be reported as such during the entire study  period.
Any severe LRTI will be reported using the SAE reporting system and SAE form, regardless of 
whether the event fulfills the criteria of an SAE.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
88
Approved , Date: 18 April 2019Serious Adverse Event
AnSAE based on ICH and European Union (EU)Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is an y untoward medical occurrence that at any dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropri ate in other situations, such as important medical events that may not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_780112]. 
These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship between the study  vaccine and the event (eg, death from anaphy laxis), the event 
must be reported as a suspected unexpected serious adverse reaction (S[LOCATION_003]R) by [CONTACT_780183]/IEC according to regulatory  and local 
requirements.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AEis considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For Ad26.RSV.preF , the expectedness of an AEwill be 
determined b y whether or not it is listed in the Investigator’s Brochure.1
Adverse Event Associated With the Use of the Vaccine
An AEis considered associated with the use of the vaccine if the attribution is related by [CONTACT_624700] 12.1.2 .
12.1.2. Attribution Definitions
Every  effort should be made by  [CONTACT_111166], ie,toadministration of the study  vaccine or to alternative causes ( eg,natural history  
of the underl ying diseases, concomitant therap y). This applies to all AEs, whether serious or 
non-serious.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
89
Approved , Date: 18 April 2019Causality  of AEs should be assessed b y the investigator based on the following:
Related : there is suspi[INVESTIGATOR_177872] a relationship between the study vaccine and the AE 
(without determining the extent of probability ); there is a reasonable possibility  that the study 
vaccine contributed to the AE.
Unrelated : there isno suspi[INVESTIGATOR_177872] a relationship between the study  vaccine and the 
AE; there are other more likely  causes and administration of the study  vaccine is not suspected to 
have contributed to the AE.
By [CONTACT_108], all solicited AEs at the injection site (local) will be considered related to the study 
vaccine administration.
12.1.3. Severity Criteria
All AEs and laboratory  data reported as AEs will be coded for severit y using the toxicity  grading 
table in Attachment 1(for Cohort 0), and in Attachment 2(for Cohort 1).Note : For Cohort 0, 
laboratory  values within local laboratory normal ranges (even if within a toxicity  grade range), or 
laboratory  values outside normal ranges that are not clinically  significant in the judgment of the 
investigator, should not be recorded as AEs. For AEs not identified in the grading table, the 
following guidelines will be applied:
Mild (Grade 1): Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with every day activities.
Moderate (Grade 2) : Sufficient discomfort is present to cause interference with norm al activity .
Severe (Grade 3): Extreme distress, causing significant impairment of functioning or 
incapacitation. Prevents normal every day activities.
Potentially life-threatening (Grade 4): Symptoms causing inability  to perform basic self-care 
functions OR medical or operative intervention indicated to prevent permanent impairment, 
persistent disability .
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
For Cohort 0, the toxicity grading scale used for laboratory  assessments is based on the FDA 
toxicity  grading table, consistent with the assessment grading used throughout the protocol. If a 
laboratory  value falls within the grading as specified in the FDA table, but also within the 
laboratory  normal limits, the value is considered as normal. For hemoglobin, both the actual 
value and the change from reference will be graded.
The severity  of solicited AEs will be graded in the diary  by [CONTACT_780184].
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
90
Approved , Date: [ADDRESS_1072390] on a sponsor study  vaccine that may require expedited reporting and/or 
safety evaluation include, but are not limited to :
Suspected abuse/misuse of a sponsor study  vaccine
Accidental or occupational exposure to a sponsor study  vaccine
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  vaccine , eg, name [CONTACT_2976])
Exposure to a sponsor study  vaccine from breast -feeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of an SAE should be recorded on the S AEpage of the eCRF .
12.3. Procedures
12.3.1. All Adverse Events
Unsolicited AEs and special reporting situations will be reported from the time a signed and 
dated ICF is obtained until 28 days (including relevant visit window, if applicable) after first 
dose of study  vacc ine,and thereafter, for 28 day s (including relevant visit window, if applicable) 
after each subsequent dose of study vaccine. Unsolicited AEs with the onset date outside the time 
frame defined above (>28 days after previous study  vaccination) that are ongoing on the day of 
the subsequent vaccination should be recorded on the eCRF AE page.
Solicited AEs will be recorded by [CONTACT_667157] [ADDRESS_1072391]’s diary  at the subsequent in-clinic visit; diary 
information will be transcribed by [CONTACT_780185]-site assessment forms in the 
eCRF.
The sponsor will evaluate any safet y information that is spontaneously  reported by [CONTACT_117197].
The investigator will monitor and check the study  data,including all AEdata (and clinical 
laboratory  data for Cohort 0),as they become available and will make determinations regarding 
the severity  of the adverse experiences and their relation to study  vaccine. All AEs will be 
deemed related to stud y vaccine or not related to study  vaccine, according to Section 12.1.2.
The investigator must review both post-injection reactogenicit y and other AEsto insure the 
prompt and complete identification of all events that require expedited reporting as SAE s, invoke 
pausing rules or are other serious and unexpected events.
All AEs, regardless of seriousness, severity , or presumed relationship to study  vaccine , must be 
recorded using medical terminology  in the source document and the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
91
Approved , Date: 18 April 2019runny  nose, sneezing, sore throat, and head congestion should be reported as “upper respi[INVESTIGATOR_28945] ”). Investigators must record in the eCRF their opi[INVESTIGATOR_667121] . All measures required for AEmanagement must be recorded in the 
source document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all S[LOCATION_003]Rs . The investigator (or sponsor where required) must report S[LOCATION_003]R s 
to the appropriate I EC/IRB that approved the protocol unless otherwise required and documented 
by [CONTACT_6179]/IRB .A S[LOCATION_003]R will be reported to regulatory  authorities unblinded. Participating 
investigators and IEC/I RB will receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
Subjects willbe provided with a “wallet (study )card” and instructed to carry  this card with th em 
for the duration of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator ’s name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor ’s name [INVESTIGATOR_1238] [ADDRESS_1072392] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All SAEs occurring from ICF signature [CONTACT_780195] [CONTACT_23829] -site personnel within [ADDRESS_1072393] 
be completed and signed by a physician from the study  site, and transmitted to the sponsor 
within 24 hours. The initial and follow -up reports of an SAE should be made by  [CONTACT_6972] (fax) .
All SAEs that have not resolved by [CONTACT_2054], or that have not resolved upon 
discontinuation of the subject ’s participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
92
Approved , Date: 18 April 2019The event can be attributed to agents other than the study  vaccine or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information canbe obtained (subject or health care
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as an SAE . 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_5186] n) that occurs during the 
course of a subject ’s participation in a study  must be reported as an SAE , except hospi[INVESTIGATOR_111074]:
Hospi[INVESTIGATOR_43717](eg, social reasons such as 
pending placement in l ong-term care facility )
Surgery or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note : Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered SAE s. Any AEthat results in a prolongation of the originall y planned 
hospi[INVESTIGATOR_23745] a new SAE .
The cause of death of a subject in a study  during the entire study  period , whether or not the event 
is expected or associated with the study  vaccine , is considered an SAE and must be reported .
12.3.3. Pregnancy  (Cohort 0 Subjects)
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by [CONTACT_1758]-site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies and ectopic pregnancy ) are considered
SAEs and must be reported using the S AEForm.
Because the effect of the study  vaccine on sperm is unknown, pregnancies in partners of male 
subjects included in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required.
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  arelisted in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
93
Approved , Date: [ADDRESS_1072394]. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personne l within [ADDRESS_1072395] report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 12.3.2 , Serious Adverse 
Events). A sample of the suspected product should be maintained for further investigation if 
requested b y the sponsor .
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY V ACCINE INFORMA TION
14.1. Physical Descr iption of Study Vaccine
A human replication -incompetent adenovirus -vectored vaccine candidate, manufactured and 
provided under the responsibility  of the sponsor ,will be assessed in this study :
Ad26.RSV .preF (JNJ -64400141 )
Ad26.RSV.preF is a replication -incompetent Ad26 containing a DNA transgene that encodes for 
the pre -fusion conformation -stabilized F protein derived from the RSV A2 strain .
For this study , Ad26.RSV.preF will beformulated as a solution for intramuscular injection. 
Ad26.RSV .preF will be supplied as a colorless frozen liquid to be thawed prior to use. 
Ad26.RSV.preF will be filled in stoppered and sealed 2 mL single -use glass vials. Injection 
volumes of 0.5 mL(1x1011vp) for adults and 0.25 mL (5x1010vp) for toddlers will be used. 
Refer to the Investigator ’s Brochure for details of the components of Ad26.RSV.preF and a list 
of excipi[INVESTIGATOR_840].
Placebo
Placebo will be supplied as sterile 0.9% saline for injection in 2 mL ampo ules.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
94
Approved , Date: [ADDRESS_1072396] be stored in a secured location under controlled temperature with no access for 
unauthorized personnel. The study  refrigerator/ freezer must be equipped with a continuous 
temperature monitor and alarm. Study  refrigerators/ freezers should be equipped with back -up 
power systems. In the event that study  vaccine is exposed to temperatures outside the specified 
temperature range, all relevant data will be sent to the sponsor to determine if the affected study 
vaccine can be used or will be replaced. The affec ted study  vaccine must be quarantined and not 
used until further instruction from the sponsor is received.
For adult subjects, injections should be administered in the deltoid. For pediatric subjects, 
injections should be administered in the anterolateral aspect of the thigh. Alternating injection 
sites will be used for the vaccinations on Day  [ADDRESS_1072397] ,or other qualified individual and administered by a study  vaccine 
administrator.
Note: the unblinded pharmacist, or other qualified individual, may also perform the 
administration, but will have no other stud y function from randomization onwards.
Further details for study  vaccine storage, preparation, handling and stability  can be found in the 
Investigational Product Preparation Instructions .
14.4. Vaccine Accountability
The investigator is responsible for ensuring that all study  vaccine received at the site is 
inventoried and accounted for throughout the study . The study  vaccine administered to the 
subject must be documented on the vaccine accountability  form. All study  vaccine will be stored 
and disposed of according to the sponsor’s instructions.
Study  vaccine must be handled in strict accordance with the protocol and the conta iner label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  vaccine must be available for verification by [CONTACT_103] ’s study -site monitor during on -site monitori ng visits. The return to the sponsor of unused 
study  vaccine will be documented on the vaccine return form. When the study  site is an 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
95
Approved , Date: [ADDRESS_1072398] also be 
documented on the vaccine return form.
Potentially  hazardous materials such as used ampoules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for vaccine accountability  purposes.
Study  vaccine should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel , or by a  hospi[INVESTIGATOR_307]/clinic pharmacist. Study  vaccine will be 
supplied only to subjects participating in the study . Returned study  vaccine must not be 
dispensed again, even to the same subject. Study  vaccine may not be relabeled or reassigned for 
use by [CONTACT_23837]. The investigator agrees neither to dispense the study  vaccine from, nor 
store it at, an y site other than the study sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator’s Brochure for Prophy lactic RSV Vaccine
Investigational Product P reparation Instructions/ Investigational Product Procedures Manual
Laboratory  Manual (including procedures for collection of nasal turbinate samples)
Trial Center File
IWRS Manual
Electronic Data Capture (eDC) Manual/eCRF completion guidelines and randomization 
instructions
Sample I CF
Subject d iaries
Ruler s
Thermometer s
RTI Symptoms Form s
Contact [CONTACT_160220](s)
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Cohort 0 only: Potential subjects will be fully informed of the risks and requirements of the study 
and, during the study , subjects will be given any new information that may affect their decision to 
continue participation. They  will be told that their consent to participate in the study  is voluntary 
and may be withdrawn at any time with no reason given and without penalty or loss of benefits to 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
96
Approved , Date: [ADDRESS_1072399] will not exceed the US Department of 
Health and Human Services (HHS) Office for Human Research Protections (OHRP), and FDA 
guidelines of 550 mL in any  eight- week period.44,45
Cohort 1 only: The parents/legal guardian of potential subjects will be fully informed of the risks 
and requirements of the study  and, during the study , will be given any new information that may 
affect their decision for their child to continue participation. They  will be told that their consent for 
their child to participate in the study  is vol untary  and may  be withdrawn at any  time with no reason 
given and without penalty or loss of benefits to which they would otherwise be entitled. Only 
parents/legal guardian who are fully able to understand the risks, benefits, and potential AEs of the 
study , and provide their consent voluntaril y will be able to enroll their child in the study .
When referring to the signing of the ICF, the terms legal guardian and legall y acceptable 
representative refer to the legall y appointed guardian of the child with authorit y to authorize 
participation in research. For each subject, his or her parent(s) (preferabl y both parents, if 
available) or legally  acceptable representative(s), as required by [CONTACT_427], must give 
written consent (permission) according to local requirements after the nature of the study  has been 
fully explained and before the performance of any study -related assessments. For the purposes of 
this study , all references to subjects who have provided consent refers to the subjects and his or her 
parent(s) or the subject ’s legal guardian(s) or legall y acceptable representative(s) who have 
provided co nsent according to this process .
The total blood volume drawn from each pediatric subject will not exceed the most stringent 
(European Medicines Agency ) guidelines for pediatric subjects in clinical trials: blood loss 
should not exceed 3% of total blood volume over four weeks, and it should not exceed 1% of 
total blood volume at any single time.12
See Section 3.4for the benefit -risk assessment.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporti ng studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
97
Approved , Date: [ADDRESS_1072400]
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator ’s Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator ’s curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its oblig ation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required local ly), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
During the study the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator ’s Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the study  vaccine
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
98
Approved , Date: 18 April 2019New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator ’s care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before imple mentation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
In this section, any reference to activities to be performed by [CONTACT_780186]/legal guardian for pediatric subjects.
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any study -
related activity . The ICF(s) that is/are used must be approved by [CONTACT_170510]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive. Finally , they will be told that the investigator will 
maintain a subject identification register for the purposes of long-term follow -up if needed and 
that their records may be accessed by [CONTACT_780187] , to the extent permitted by [CONTACT_43773](s) or regulations. By [CONTACT_111178] . It also denotes 
that the subject agrees to allow his or her study  physician to recontact [CONTACT_543440] y evaluations, if needed.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
99
Approved , Date: [ADDRESS_1072401]’ s personall y dated signature. After having obtained the consent, a copy 
of the I CF must be given to the subject.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulat ions. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibili ties require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject (or parent/legal guardian for pediatric subjects)
includes explicit consent for the processing of personal data and for the investigator/institution to 
allow direct access to his or her original medical records (source data/documents) for study -
related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject (or parent/legal guardian for pediatric subjects) has the right to request through the 
investigator access to his or her personal data and the right to request rectification of any data 
that are not correct orcomplete. Reasonable steps will be taken to respond to such a request, 
taking into consideration the nature of the request, the conditions of the study , and the applicable 
laws and regulations.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples , including samples from subjects who were 
screened but not randomized, will only be used to understand Ad26.RSV.preF , to understand 
RSV , and to develop tests/assay s related to Ad26.RSV.preF and RSV .The research may  begin at 
any time during the study or the post -study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( refer to Section 10.2).
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
100
Approved , Date: [ADDRESS_1072402] not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_307510] (s), which will beprovided as a separate
document . Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_233869]. The data recorded 
in the eCRF and source documents will reflect any departure from the protoc ol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Pre -study Documentation
The following documents must be provided to the sponsor before shipment of study  vaccine to 
the study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_978].
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851] .
Name [CONTACT_23875]/IRB, includ ing a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
101
Approved , Date: 18 April 2019member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
Regulatory  authority  approval or notification, if applicable .
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable .
Documentation of investigator qualifications (eg, curriculum vitae).
Completed investigator financial disclosure form from the PI, where required.
Signed and dated Clinical Trial Agreement, which includes the financial agreement.
Any other documentation required by  [CONTACT_427].
Geneticall y modified organism (GMO) and/or Institutional Biosafet y Committee (IBC) 
approval, if applicable .
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators .
Documentation o f subinvestigator qualifications (eg, curriculum vitae).
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable .
Local laboratory  documentation demonstrat ing competence and test reliability 
(eg,accreditation/license), if applicable .
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document s consistent in the typeand level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
102
Approved , Date: 18 April 2019informed consent; dates of visits; results of safety  and immunogenicity parameters as required by  
[CONTACT_760]; record of all AEs and follow -up of AEs; concomitant medication; vaccine
receipt/dispensing/return records; study  vaccine administration informat ion; and date of study 
completion and reason for early  discontinuation of study  vaccine or withdrawal from the study , if 
applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The subject diary  used to collect information regarding solicited events after vaccination will be 
considered source data. At the visits at [ADDRESS_1072403] diary  will be reviewed by  [CONTACT_093] ;diary  information will be transcribed by  [CONTACT_780188] .
An eSource system may be utilized, which contains data traditionally  maintained in a hospi[INVESTIGATOR_90761] (eg, electronic source documents) as well as the clinical 
study -specific data fields as determined by [CONTACT_760]. This data is electronically extracted for 
use by [CONTACT_456]. If eSource is utilized, references made to the eCRF in the protocol include 
the eSource system but information collected through eSource may not be limited to that found 
in the eCRF.
17.5. Case Report Form Completion
Case report forms are prepared and provided by  [CONTACT_66888].
AlleCRF entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify  that all data entries in the eCRF are accurate 
and correct.
The study  data will be transcribed by [CONTACT_3449]-sitepersonnel from the source documents onto an 
eCRF, if applicable. Study -specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of theeCRF . Any 
such worksheets will become part of the subject ’s source document s. Data must be entered into
eCRF in English. TheeCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
If necessary , queries will be generated in the eDC tool. If corrections to aneCRF are needed 
after the i nitial entry  into the eCRF , this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
103
Approved , Date: 18 April 2019Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investi gators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study ,and periodic monitoring visits by [CONTACT_456]. Written 
instructions will be provided for collection, handling, storage, and s hipment of samples.
Guidelines foreCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRF for accuracy  and completeness during 
on-site monitoring visits and after transmission to the sponsor; an y discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain alleCRF
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_43785]. It is the responsibility  of the sponsor to inform the 
investig ator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the s ponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitor ing visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study  site. The first 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
104
Approved , Date: [ADDRESS_1072404]-initiation visit will be made as soon as possible after enrollment has begun. At these visits,
the monitor will compar e the data entered into the eCRF with the source documents
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician ’s office medical records) . The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the
eCRF are known to the sponsor and study -site personnel and are accessible for verification by 
[CONTACT_43786] -site contact. If electronic records are maintained at the study site, the method 
of verification must be discussed with the study -site personnel .
Direct access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source document swill 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The end of the active phase will be when the last subject completes the visit 6 months after the 
final dose (Visit 8 Cohort 0; Visit 9 for Cohort 1). The end of the study  will be the last subject’s 
last visit (by [CONTACT_756]) at the end of the safet y follow -up phase (1year after the first dose) . The 
study  is considered completed with the last visit for the last subject participating in the study . 
The final data from the study  site will be sent to the sponsor (or designee) after completion of the 
final subject visit at that study  site, in the time frame specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the int ended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor ’s procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  vaccine development
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
105
Approved , Date: 18 April 201917.10. On-Site A udits
Representatives of the sponsor ’s clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding Ad26.RSV.preF or the 
sponsor ’s operations (eg,patent application , formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by [CONTACT_66894], and any data generated as a result of this study , areconsidered 
confidentia l and remain the sole property  of the sponsor. The investigator agrees to maintain this 
information in confidence and use this information only to accomplish this study , and will not 
use it for other purposes without the sponsor ’s prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_111181]26.RSV.preF , and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies . To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_624708]-protocol . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results ofanaly ses performed after 
the Clinical Study  Report has been issued will be reported in a separate report and will not 
require a revision of the Clinical Study  Report. Study  subject identifiers will not be used in 
publication o f results. Any work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by [CONTACT_23868]) shall be the propert y of the sponsor as author and owner of 
copy right in such work.
Arrangements on publication policy  will be addressed in the Clinical Trial Agreement.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
106
Approved , Date: 18 April 2019Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
107
Approved , Date: 18 April 2019REFERENCES
1. Investigator's Brochure: Prophylactic RSV Vaccine. Edition 4. Janssen Vaccines & Prevention B.V. 
2. Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS -402, induces robust and 
polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med. 2010:181;1407 -1417.
3. Anderson LJ, Dormitzer PR, Nokes DJ, et al. Strategic priorities for respi[INVESTIGATOR_4345] (RSV) vaccine 
development. Vaccine. 2013:[ADDRESS_1072405] 2;B209 -215.
4. Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a 
recombinant adenovirus serotype 26 HIV -1 Env vaccine (IPCAVD 001). J Infect Dis. 2013:207;240 -247.
5. Barouch DH, Liu J, Peter L, et al. Characterization of hu moral and cellular immune responses elicited by a 
recombinant adenovirus serotype 26 HIV -1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis. 
2013:207;248 -256.
6. Centers for Disease Control and Prevention. Respi[INVESTIGATOR_130320] (RSV) -Infection and 
Incidence. Available at: http://www.cdc.gov/rsv/about/infection.html (last accessed 05 January 2017).
7. Centers for Disease Control and Prevention. WHO Growth Standards Recommended for Use in the U.S. for 
Infants and Children 0 to 2 Years of A ge. Available at: https://www.cdc.gov/growthcharts/who_charts htm 
(last accessed 02 March 2017).
8. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respi[INVESTIGATOR_780113] a trivalent parainfluenza virus vaccin e in a pediatric population. Am J Epi[INVESTIGATOR_5541]. 1969:89;449 -
463.
9. Chung AW, Ghebremichael M, Robinson H, et al. Polyfunctional Fc -effector profiles mediated by [CONTACT_780189]144 and VAX003 vaccines. Sci Transl Med. 2014:6;228ra238.
10. Creech CB, Dekker CL, Ho D, et al. Randomized, placebo -controlled trial to assess the safety and 
immunogenicity of an adenovirus type 35 -based circumsporozoite malaria vaccine in healthy adults. Hum 
Vaccin Immunother. 2013:9;2548 -2557.
11. European Center for Disease Prevention and Control. Vaccine Schedule. Available at: http://vaccine -
schedule.ecdc.europa.eu/Pages/Scheduler.aspx (last accessed 17 March 2017).
12. European Medicines Agency. Ethical considerations for clinical trials on medicinal products conducted with 
the paediatric population. Available at: http://ec.europa.eu/health/files/eudralex/vol -
10/ethical_considerations_en.pdf (last accessed 05 January 2017).
13. Fulginiti VA, Eller JJ, Sieber OF, et al. Respi[INVESTIGATOR_327908]. I. A field trial of two inactivated 
respi[INVESTIGATOR_327909]; an aqueous trivalent parainfluenza virus vaccine and an alum -precipi[INVESTIGATOR_780114]. Am J Epi[INVESTIGATOR_5541]. 1969:89;435 -448.
14. Gidudu JF, Walco GA, Taddio A, et al. Immunization site pain: case defi nition and guidelines for collection, 
analysis, and presentation of immunization safety data. Vaccine. 2012:30;4558- 4577.
15. Gilman MS, Castellanos CA, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B 
cells of naturally infected ad ult donors. Sci Immunol. 2016:1;
16. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respi[INVESTIGATOR_14256]. Am J Dis Child. 1986:140;543 -546.
17. Graham BS, Modjarrad K, Mclellan JS. Novel antigens for RSV vaccines. Cu rr Opin Immunol. 2015:35;30 -38.
18. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respi[INVESTIGATOR_667122]. N Engl J Med. 2009:360;[ADDRESS_1072406] Operating Procedure: TV -SOP-[ZIP_CODE]. 
20. Janssen Research and Development. Temporary Suspension, Premature Study Termination, and Study Closure. 
Standard Operating Procedure: TV- SOP-[ZIP_CODE]. 
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
108
Approved , Date: 18 April 201921. Kapi[INVESTIGATOR_300012], Mitchell RH, Cha nock RM, Shvedoff RA, Stewart CE. An epi[INVESTIGATOR_667123] (RS) virus infection in children previously vaccinated with an 
inactivated RS virus vaccine. Am J Epi[INVESTIGATOR_5541]. 1969:89;405 -421.
22. Kim  HW, Canchola JG, Brandt CD, et al. Respi[INVESTIGATOR_780115]. Am J Epi[INVESTIGATOR_5541]. 1969:89;422 -434.
23. Kohl KS, Walop W, Gidudu J, et al. Induration at or near injection site: case definition an d guidelines for 
collection, analysis, and presentation of immunization safety data. Vaccine. 2007:25;5839 -5857.
24. Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for 
collection, analysis and presentation of immunization safety data. Vaccine. 2007:25;5858 -5874.
25. Krarup A, Truan D, Furmanova -Hollenstein P, et al. A highly stable prefusion RSV F vaccine derived from 
structural analysis of the fusion mechanism. Nat Commun. 2015:6;8143.
26. Kutsaya A, Teros -Jaakkol a T, Kakkola L, et al. Prospective clinical and serological follow -up in early 
childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 
[ADDRESS_1072407]. 2016;144:[ADDRESS_1072408] the preactive form of respi[INVESTIGATOR_667124]. Proc Natl Acad Sci U S A. 
2012:109;3089 -3094.
28. Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and 
guidelines of data collection, analysis, and presentation. Vaccine. 2004:22;551 -556.
29. Milligan ID, Gibani MM, Se well R, et al. Safety and immunogenicity of novel adenovirus type 26 -and 
modified vaccinia ankara -vectored ebola vaccines: a randomized clinical trial. JAMA. 2016:315;1610 -1623.
30. Modjarrad K, Giersing B, Kaslow  DC, et al. WHO consultation on Respi[INVESTIGATOR_333908] a World Health Organizat ion Meeting held on 23 -24 March 2015. Vaccine. 
2016:34;190 -197.
31. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by 
[CONTACT_328057] -inactivated vaccines. Nat Med. 2006:12;905 -907.
32. Nair H, Nokes DJ, Gessner BD, e t al. Global burden of acute low er respi[INVESTIGATOR_780116]: a systematic review and meta -analysis. Lancet. 2010:375;1545 -1555.
33. Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F -specific antibodies determine the magnitude of RSV 
neutralizing activity in human sera. Sci Transl Med. 2015:7;309ra162.
34. Ouedraogo A, Tiono AB, Kargougou D, et al. A phase 1b randomized, controlled, double- blinded dosage-
escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based 
circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 
2013:8;e78679.
35. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respi[INVESTIGATOR_4345] -related illness in the 
US: an analysis of national databases. Pharmacoeconomics. 2004:22;275 -284.
36. Peebles RS, Jr. Viral infections, atopy, and asthma: is there a causal relationship? J Allergy Clin Immunol. 
2004:113;S15 -18.
37. Radosevic K, Rodriguez A, Lemckert AA, e t al. The Th1 immune response to Plasmodium falciparum 
circumsporozoite protein is boosted by [CONTACT_667160] 35 and 26 w ith a homologous insert. Clin Vaccine 
Immunol. 2010:17;1687 -1694.
38. Regnier SA, Huels J. Association betw een respi[INVESTIGATOR_780117]: systematic review and meta -analysis. Pediatr Infect Dis J. 2013:32;[ADDRESS_1072409], et al. Bronchiolitis -associated hospi[INVESTIGATOR_469022], 1980 -
1996. JAMA. 1999 :282;1440 -1446.
40. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respi[INVESTIGATOR_780118] 13. Am J Respir Crit Care Med. 2005:171;137 -141.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
109
Approved , Date: [ADDRESS_1072410] Dis J. 
2015:34;[ADDRESS_1072411] of respi[INVESTIGATOR_780119]. J Allergy Clin Immunol. 2010:126;256 -262.
43. Simoes EA, Groothuis JR, Carbonell -Estrany X, et al. Palivizumab prophylaxis, respi[INVESTIGATOR_4345], 
and subsequent recurrent wheezing. J Pediatr. 2007:151;[ADDRESS_1072412] Dis J. 
2012:31;5 -9.
45. US D epartment of Health and Human Services. Office for Human Research Protections -OHRP Expedited 
Revie w Categories (1998). Available at: http://www hhs.gov/ohrp/regulations -and-policy/guidance/categories -
of-research -expedited -review -procedure -1998/index html (last accessed 05 January 2017).
46. US Food and Drug Administration. Conditions for IRB Use of Expedited Revie w. Available at: 
http://www.fda.gov/ScienceResearch/SpecialTopi[INVESTIGATOR_1102]/RunningClinicalTrials/GuidancesInformationSheetsandNo
tices/ucm118099 htm (last acc essed 05 January 2017).
47. Data on file.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
110
Approved , Date: 18 April 2019Attachment 1: Toxicity Tables for Cohort 0
From the FDA Guidance document “Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials” (September 2007)
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
111
Approved , Date: 18 April 2019A: Tables for Clinical Abnormalities
Local Reaction to
Injectable ProductMild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening
(Grade 4 )
Pain Does not interfere
with activityRepeated use of 
non-narcotic
pain reliever
> 24 hours or
interferes with
activityAny use of
narcotic pain
reliever or
prevents daily
activityEmergency room
visit or
hospi[INVESTIGATOR_780120]/redness* 2.5 –5 cm 5.1 –10 cm > 10 cm Necrosis or
exfoliative
dermatitis
Induration/swelling** 2.5 –5 cm and
does not interfere
with activity5.1 –10 cm or
interferes with
activity> 10 cm or
prevents daily
activityNecrosis
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as a
continuous variable.
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement.
Vital Signs * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening
(Grade 4 )
Fever** (°C)
Fever** (°F)38.0 –38.4
100.4 – 101.138.5 –38.9
101.2 – 102.039.0 –40
102.1 – 104>40
>104
Tachycardia -beats per 
minute101 – 115 116 – 130 >130 Emergency room visit or 
hospi[INVESTIGATOR_177904] -beats per 
minute***50 –54 45 –49 < 45 Emergency room visit or 
hospi[INVESTIGATOR_177905] (systolic) 
-mm Hg141 – 150 151 – 155 >155 Emergency room visit or 
hospi[INVESTIGATOR_177906] 
(diastolic) -mm Hg91 –95 96 –100 >100 Emergency room visit or 
hospi[INVESTIGATOR_177907] (systolic) 
-mm Hg85 –89 80 –84 < 80 Emergency room visit or 
hospi[INVESTIGATOR_177908] -
breaths per minute17 –20 21 –25 >25 Intubation
* Subject should be at rest for all vital sign measurements.
** Oral temperature; no recent hot or cold beverages or smoking.
*** When resting heart rate is between [ADDRESS_1072413] populations, for example, conditioned athletes.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
112
Approved , Date: 18 April 2019Systemic
(General)Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening 
(Grade 4 )
Nausea/vomiting No interference 
with activity or 1 
-2 epi[INVESTIGATOR_1841]/24 
hoursSome interference 
with activity or >2 
epi[INVESTIGATOR_1841]/24 hoursPrevents daily 
activity, requires 
outpatient IV 
hydrationEmergency room visit or 
hospi[INVESTIGATOR_780121] 2 -3 loose stools 
or <400 gms/24 
hours4 -5 stools or 400 -
800 gms/24 hours6 or more w atery 
stools or 
>800gms/24 
hours or requires 
outpatient IV 
hydrationEmergency room visit or 
hospi[INVESTIGATOR_624650]-narcotic pain 
reliever >24 hours 
or some 
interference with 
activitySignificant; any 
use of narcotic 
pain reliever or 
prevents daily 
activityEmergency room visit or 
hospi [INVESTIGATOR_93276]; 
prevents daily 
activityEmergency room visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityEmergency room visit or 
hospi[INVESTIGATOR_624651]
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -threatening 
(Grade 4 )
Illness or clinical AE
(as defined according 
to applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
requires medical 
interventionEmergency room visit or 
hospi[INVESTIGATOR_780122]1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
113
Approved , Date: 18 April 2019B: Tables for Laboratory Abnormalities
The grading scale used for laboratory assessments is based on the FDA Guidance document “Toxicity 
Grading Scale from Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials”. Any laboratory value shown as a “graded” value in the table that is within the central laboratory
normal ranges will not be graded for severity or recorded as AE. For hemoglobin, both the actual value 
and the change from reference will be graded. For the change from reference, the corresponding actual 
value should also be at least Grade 1.
Serum * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Sodium –
Hyponatremia -mEq/L132 – 134 130 – 131 125 – 129 < 125
Sodium –
Hypernatremia -
mEq/L144 – 145 146 – 147 148 – 150 > 150
Potassium –
Hyperkalemia -mEq/L5.1 –5.2 5.3 –5.4 5.5 –5.6 > 5.6
Potassium –
Hypokalemia -mEq/L3.5 –3.6 3.3 –3.4 3.1 –3.2 < 3.1
Glucose –
Hypoglycemia -mg/dL65 –69 55 –64 45 –54 < 45
Glucose –
Hyperglycemia Fasting 
-mg/dL100 – 110 111 – 125 > 125 Insulin requirements 
or hyperosmolar 
coma
Random Glucose -
mg/dL110 – 125 126 – 200 >200
Blood Urea Nitrogen 
BUN - mg/dL23 –26 27 –31 > 31 Requires dialysis
Creatinine -mg/dL 1.5 –1.7 1.8 –2.0 2.1 –2.5 > 2.5 or requires 
dialysis
Calcium –
hypocalcemia -mg/dL8.0 –8.4 7.5 –7.9 7.0 –7.4 < 7.0
Calcium –
hypercalcemia -mg/dL10.5 –11.0 11.1 –11.5 11.6 –12.0 > 12.0
Magnesium –
hypomagnesemia -
mg/dL1.3 –1.5 1.1 –1.2 0.9 –1.0 < 0.9
Phosphorous –
hypophosphatemia -
mg/dL2.3 –2.5 2.0 –2.2 1.6 –1.9 < 1.6
CPK -mg/dL 1.25 –1.[ADDRESS_1072414]*** 1.6 –3.[ADDRESS_1072415] 3.1 –[ADDRESS_1072416] > [ADDRESS_1072417]
Albumin –
Hypoalbuminemia -
g/dL2.8 –3.1 2.5 –2.7 < 2.5 --
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
114
Approved , Date: 18 April 2019Serum * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Total Protein –
Hypoproteinemia -
g/dL5.5 –6.0 5.0 –5.4 < 5.0 --
Alkaline phosphate –
increase by [CONTACT_12245]1.1 –2.[ADDRESS_1072418] 2.1 –3.[ADDRESS_1072419] 3.1 –[ADDRESS_1072420] > [ADDRESS_1072421]
Liver Function Tests –
ALT, AST increase by 
[CONTACT_12245]1.1 –2.[ADDRESS_1072422] 2.6 –5.[ADDRESS_1072423] 5.1 –[ADDRESS_1072424] > [ADDRESS_1072425]
Bilirubin –when 
accompanied by [CONTACT_780190]1.1 –1.[ADDRESS_1072426] 1.26 –1.[ADDRESS_1072427] 1.51 –1.[ADDRESS_1072428] > 1.[ADDRESS_1072429]
Bilirubin –when Liver 
Function Test is 
norm al; increase by 
[CONTACT_12245]1.1 –1.[ADDRESS_1072430] 1.6 –2.[ADDRESS_1072431] 2.0 –3.[ADDRESS_1072432] > 3.[ADDRESS_1072433]
Cholesterol 201 – 210 211 – 225 > 226 --
Pancreatic enzymes –
amylase, lipase1.1 –1.[ADDRESS_1072434] 1.6 –2.[ADDRESS_1072435] 2.1 –5.[ADDRESS_1072436] > 5.[ADDRESS_1072437]
* The laboratory values provided in the tables serve as guidelines and are dependent upon central laboratory normal parameters. 
Central laboratory normal reference ranges should be provided to demonstrate that they are appropriate.
** The clinical signs or symptoms associated with laboratory abnormalities might result in characterization of the laboratory
abnormalities as potentially life-threatening (Grade 4). For example. a low sodium value that falls within a Grade 3 parameter 
(125-129 mE/L) should be recorded as a Grade [ADDRESS_1072438] had a new seizure associated with the low 
sodium value.
***ULN is the upper limit of the normal range.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
115
Approved , Date: 18 April 2019Hem atology * Mild
(Grade 1 )Moderate
(Grade 2 )Severe
(Grade 3 )Potentially Life -
threatening
(Grade 4 ) **
Hem oglobin (Female) -
gm/dL11.0 –12.0 9.5 –10.9 8.0 –9.4 < 8.0
Hem oglobin (Female) 
change from baseline 
value -gm/dLAny decrease –1.5 1.6 –2.0 2.1 –5.0 > 5.0
Hem oglobin (Male) -
gm/dL12.5 –13.5 10.5 –12.4 8.5 –10.4 < 8.5
Hem oglobin (Male) 
change from baseline 
value -gm/dLAny decrease –1.5 1.6 –2.0 2.1 –5.0 > 5.0
WBC Increase -
cell/mm310,800 –15,000 15,001 –20,000 20,001 –25,000 > 25,000
WBC Decrease -
cell/mm32,500 – 3,500 1,500 – 2,499 1,000 – 1,499 < 1,000
Lymphocytes Decrease 
- cell/mm3750 –1,000 500 – 749 250 – 499 < 250
Neutrophils Decrease -
cell/mm31,500 – 2,000 1,000 – 1,499 500 – 999 < 500
Eosinophils -cell/mm3 650 –1500 1501 –5000 > 5000 Hypereosinophilic
Platelets Decreased -
cell/mm3125,000 –140,000 100,000 –124,000 25,000 –99,000 < 25,000
PT -increase by [CONTACT_12245] 
(prothrombin time)1.0 –1.[ADDRESS_1072439]** 1.11 –1.[ADDRESS_1072440] 1.21 –1.[ADDRESS_1072441] > 1.[ADDRESS_1072442]
PTT -increase by 
[CONTACT_12245] (partial 
thromboplastin time)1.0 –1.[ADDRESS_1072443] 1.21 –1.[ADDRESS_1072444] 1.41 –1.[ADDRESS_1072445] > 1.[ADDRESS_1072446]
Fibrinogen increase -
mg/dL400 – 500 501 – 600 > 600 --
Fibrinogen decrease -
mg/dL150 – 200 125 – 149 100 – 124 < 100 or associated 
with gross bleeding 
or disseminated 
intravascular 
coagulation (DIC)
* The laboratory values provided in the tables serve as guidelines and are dependent upon central laboratory normal para meters. 
Central laboratory normal reference ranges should be provided to demonstrate that they are appropriate.
** ULN is the upper limit of the normal range.
VAC1819 4(Ad26.RSV.preF)
Clinical Protocol Amendment 4 VAC18194RSV2001
120
Approved , Date: [ADDRESS_1072447] of the study, and the obligations of confidentiality.
Coordi nating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: [CONTACT_1782]:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: [CONTACT_1782]:
(Day Month Year)
Sponsor ’s Responsible Medical Officer:
Nam e (typed or printed):
Institution: Janssen Research andDevelopment
Signature: [CONTACT_184956]:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.
LASTPAGE
[COMPANY_003]
  
SIGNATURES 
    
Signed by  [CONTACT_111198]  
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
18Apr2019, 10:33:33 AM, UTC
Document Approval
[COMPANY_003]